Chr	Start	End	Ref	Alt	Func.refGene	Gene.refGene	GeneDetail.refGene	ExonicFunc.refGene	AAChange.refGene	pLi.refGene	pRec.refGene	pNull.refGene	Disease_description.refGene	P(HI).refGene	P(rec).refGene	RVIS.refGene	RVIS_percentile.refGene	GDI.refGene	GDI-Phred.refGene	SIFT_score	SIFT_converted_rankscore	SIFT_pred	Polyphen2_HDIV_score	Polyphen2_HDIV_rankscore	Polyphen2_HDIV_pred	Polyphen2_HVAR_score	Polyphen2_HVAR_rankscore	Polyphen2_HVAR_pred	LRT_score	LRT_converted_rankscore	LRT_pred	MutationTaster_score	MutationTaster_converted_rankscore	MutationTaster_pred	MutationAssessor_score	MutationAssessor_score_rankscore	MutationAssessor_pred	FATHMM_score	FATHMM_converted_rankscore	FATHMM_pred	PROVEAN_score	PROVEAN_converted_rankscore	PROVEAN_pred	VEST3_score	VEST3_rankscore	MetaSVM_score	MetaSVM_rankscore	MetaSVM_pred	MetaLR_score	MetaLR_rankscore	MetaLR_pred	M-CAP_score	M-CAP_rankscore	M-CAP_pred	CADD_raw	CADD_raw_rankscore	CADD_phred	DANN_score	DANN_rankscore	fathmm-MKL_coding_score	fathmm-MKL_coding_rankscore	fathmm-MKL_coding_pred	Eigen_coding_or_noncoding	Eigen-raw	Eigen-PC-raw	GenoCanyon_score	GenoCanyon_score_rankscore	integrated_fitCons_score	integrated_fitCons_score_rankscore	integrated_confidence_value	GERP++_RS	GERP++_RS_rankscore	phyloP100way_vertebrate	phyloP100way_vertebrate_rankscore	phyloP20way_mammalian	phyloP20way_mammalian_rankscore	phastCons100way_vertebrate	phastCons100way_vertebrate_rankscore	phastCons20way_mammalian	phastCons20way_mammalian_rankscore	SiPhy_29way_logOdds	SiPhy_29way_logOdds_rankscore	Interpro_domain	GTEx_V6_gene	GTEx_V6_tissue	Otherinfo
chr1	1452551	1452551	G	A	exonic	ATAD3A	.	nonsynonymous SNV	ATAD3A:NM_018188:exon3:c.G287A:p.R96Q	0.040130598	0.959596763	0.000272639	.	0.3012	0.10317	0.119404819	62.20806794	1511.84536	7.22185	0.491	0.080	T	0.0	0.026	B	0.0	0.013	B	0.000	0.003	N	1	0.090	P	-0.895	0.014	N	-2.18	0.867	D	-0.11	0.087	N	0.08	0.072	-0.919	0.458	T	0.002	0.006	T	.	.	.	-2.157	0.006	0.001	0.618	0.066	0.000	0.002	N	c	-2.249	-2.328	0.999	0.386	0.461	0.090	0	-4.25	0.035	-2.319	0.012	-4.718	0.000	0.000	0.063	0.000	0.016	3.959	0.088	.	.	.	0.5	53	24	chr1	1452551	chr1:1452551	G	A	53	PASS	AN=2;DP=24	GT	0/1
chr1	6514592	6514592	A	G	intronic	ESPN	.	.	.	0.002553841	0.982377837	0.015068321	DISEASE: Deafness, autosomal recessive, 36, with or without vestibular involvement (DFNB36) [MIM:609006]: A form of non- syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNB36 is characterized by prelingual, profound hearing loss, and vestibular areflexia in some patients. {ECO:0000269|PubMed:15286153, ECO:0000269|PubMed:15930085}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09981	0.12971	.	.	1569.90563	7.33096	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	103	88	chr1	6514592	chr1:6514592	A	G	103	PASS	AN=2;DP=88	GT	0/1
chr1	7861157	7861157	-	T	intronic	PER3	.	.	.	2.19E-10	0.99157171	0.008428289	.	0.17974	.	1.352134556	94.35598018	722.42393	5.33625	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	38	chr1	7861157	chr1:7861157	G	GT	41	PASS	AN=2;DP=38	GT	0/1
chr1	9083026	9083026	C	T	exonic	SLC2A7	.	nonsynonymous SNV	SLC2A7:NM_207420:exon3:c.G262A:p.G88S	2.99E-17	0.000633282	0.999366718	.	0.08611	0.17345	1.692094639	96.42014626	924.8755	5.90621	0.004	0.654	D	1.0	0.899	D	0.998	0.875	D	0.000	0.843	D	0.990	0.411	D	3.465	0.926	M	0.36	0.579	T	-5.29	0.843	D	0.744	0.740	0.017	0.826	D	0.412	0.760	T	0.012	0.299	T	6.084	0.838	28.2	0.998	0.918	0.893	0.494	D	c	0.413	0.224	1.000	0.747	0.526	0.212	0	3.94	0.446	3.066	0.494	0.931	0.441	0.980	0.350	0.114	0.194	14.349	0.661	Major facilitator superfamily domain	.	.	0.5	72	97	chr1	9083026	chr1:9083026	C	T	72	PASS	AN=2;DP=97	GT	0/1
chr1	20414964	20414965	TT	-	intronic	PLA2G5	.	.	.	0.000190275	0.474147037	0.525662688	DISEASE: Fleck retina, familial benign (FRFB) [MIM:228980]: An autosomal recessive condition associated with a distinctive retinal appearance and no apparent visual or electrophysiologic deficits. Affected individuals are asymptomatic, but fundus examination reveals a striking pattern of diffuse, yellow-white, fleck-like lesions extending to the far periphery of the retina but sparing the foveal region. {ECO:0000269|PubMed:22137173}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.11251	.	-0.317668748	31.45789101	25.27033	0.82614	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	20	chr1	20414963	chr1:20414963	CTT	C	47	PASS	AN=2;DP=20	GT	0/1
chr1	27107159	27107159	G	A	exonic	ARID1A	.	nonsynonymous SNV	ARID1A:NM_006015:exon20:c.G6770A:p.R2257Q,ARID1A:NM_139135:exon20:c.G6119A:p.R2040Q	0.999999997	3.36E-09	9.91E-23	.	0.54895	0.15082	-2.670076378	0.743099788	409.71816	4.24329	0.001	0.784	D	1.0	0.899	D	0.996	0.832	D	0.000	0.843	D	1.000	0.588	D	2.195	0.620	M	0.86	0.468	T	-3.54	0.686	D	0.412	0.936	-0.523	0.678	T	0.277	0.649	T	0.016	0.368	T	4.965	0.668	25.1	0.999	0.994	0.973	0.739	D	c	0.804	0.774	1.0	0.983	0.707	0.730	0	4.6	0.564	9.665	0.979	0.902	0.416	1.000	0.715	1.000	0.888	17.964	0.890	Armadillo-type fold	.	.	0.5	110	51	chr1	27107159	chr1:27107159	G	A	110	PASS	AN=2;DP=51	GT	0/1
chr1	44131262	44131262	-	A	intronic	KDM4A	.	.	.	0.999993865	6.13E-06	1.77E-15	.	0.18092	0.10689	-0.020150552	52.25288983	135.04266	2.52863	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	20	chr1	44131262	chr1:44131262	T	TA	41	PASS	AN=2;DP=20	GT	0/1
chr1	52879584	52879584	A	G	exonic	PRPF38A	.	nonsynonymous SNV	PRPF38A:NM_032864:exon6:c.A643G:p.R215G	0.996467619	0.003532335	4.65E-08	.	0.0439	0.10543	-0.207437529	38.2814343	7.72909	0.28518	0.073	0.348	T	0.029	0.185	B	0.026	0.195	B	0.000	0.843	D	1.000	0.506	D	0.55	0.145	N	0.98	0.421	T	-1.36	0.338	N	0.541	0.579	-1.087	0.060	T	0.069	0.282	T	0.019	0.416	T	2.800	0.397	21.4	0.991	0.518	0.885	0.482	D	c	-0.427	-0.267	0.047	0.147	0.707	0.730	0	1.49	0.219	2.415	0.440	0.242	0.267	1.000	0.715	0.960	0.441	14.090	0.644	Pre-mRNA-splicing factor 38, C-terminal	.	.	0.5	93	148	chr1	52879584	chr1:52879584	A	G	93	PASS	AN=2;DP=148	GT	0/1
chr1	53308644	53308644	A	C	exonic	ZYG11A	.	nonsynonymous SNV	ZYG11A:NM_001004339:exon1:c.A89C:p.Q30P	.	.	.	.	0.11936	.	0.837848571	88.22835574	323.85912	3.82518	0.006	0.614	D	0.911	0.484	P	0.461	0.446	P	0.199	0.166	U	1	0.810	D	2.095	0.583	M	0.89	0.456	T	-1.43	0.352	N	0.626	0.650	-1.062	0.114	T	0.091	0.348	T	0.041	0.598	D	5.178	0.699	25.5	0.991	0.531	0.671	0.331	D	c	0.116	0.130	1.000	0.747	0.564	0.319	0	4.03	0.459	1.125	0.307	0.939	0.529	1.000	0.715	0.987	0.523	9.272	0.367	.	.	.	0.5	.	65	chr1	53308644	chr1:53308644	A	C	.	PASS	AN=0;DP=65	GT	0/1
chr1	54831116	54831116	G	A	intronic	SSBP3	.	.	.	0.999756196	0.000243804	3.40E-10	.	0.15537	0.08395	-0.648365105	16.35999056	29.52993	0.94347	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr1	54831116	chr1:54831116	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr1	114025434	114025434	-	T	intronic	MAGI3	.	.	.	0.570580157	0.429419836	7.05E-09	.	0.93064	0.10933	-0.925889687	9.754659118	136.27247	2.53739	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	96	chr1	114025434	chr1:114025434	C	CT	62	PASS	AN=2;DP=96	GT	0/1
chr1	150849068	150849068	-	C	UTR5	ARNT	NM_001668:c.-26_-25insG;NM_001350225:c.-18145_-18144insG;NM_001350224:c.-18135_-18134insG;NM_001350226:c.-18145_-18144insG;NM_001197325:c.-26_-25insG;NM_178427:c.-26_-25insG;NM_001286036:c.-26_-25insG;NM_001286035:c.-18135_-18134insG	.	.	0.976348195	0.023651796	8.24E-09	.	0.28663	0.22862	-0.534490515	20.70063694	99.66528	2.16216	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	63	chr1	150849068	chr1:150849068	G	GC	60	PASS	AN=2;DP=63	GT	0/1
chr1	151022895	151022895	-	T	intronic	C1orf56	.	.	.	0.001317284	0.650219074	0.348463642	.	0.07271	0.07189	0.327131069	73.27199811	200.14551	3.05763	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	56	chr1	151022895	chr1:151022895	A	AT	53	PASS	AN=2;DP=56	GT	0/1
chr1	164326647	164326647	G	A	intergenic	LOC100422212;PBX1	dist=933666;dist=201950	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	79	82	chr1	164326647	chr1:164326647	G	A	79	PASS	AN=2;DP=82	GT	0/1
chr1	167893778	167893778	-	A	intronic	MPC2	.	.	.	0.449429467	0.522427122	0.028143411	.	0.22019	0.09609	0.501689326	79.7888653	143.21224	2.60927	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	81	chr1	167893778	chr1:167893778	G	GA	41	PASS	AN=2;DP=81	GT	0/1
chr1	179271949	179271949	T	-	intronic	SOAT1	.	.	.	1.67E-05	0.96658748	0.03339587	.	0.09058	0.50106	-0.286522835	33.47487615	1212.8663	6.5907	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	18	chr1	179271948	chr1:179271948	AT	A	53	PASS	AN=2;DP=18	GT	0/1
chr1	181768572	181768572	G	A	UTR3	CACNA1E	NM_001205293:c.*602G>A;NM_001205294:c.*602G>A;NM_000721:c.*602G>A	.	.	1	6.60E-14	1.68E-33	.	0.53292	0.32174	-2.708891704	0.713611701	325.12803	3.83322	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr1	181768572	chr1:181768572	G	A	.	PASS	AN=0;DP=38	GT	0/1
chr1	196709736	196709736	-	T	intronic	CFH	.	.	.	0.999630968	0.000369032	3.16E-13	DISEASE: Complement factor H deficiency (CFHD) [MIM:609814]: A disorder that can manifest as several different phenotypes, including asymptomatic, recurrent bacterial infections, and renal failure. Laboratory features usually include decreased serum levels of factor H, complement component C3, and a decrease in other terminal complement components, indicating activation of the alternative complement pathway. It is associated with a number of renal diseases with variable clinical presentation and progression, including membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. {ECO:0000269|PubMed:10803850, ECO:0000269|PubMed:11158219, ECO:0000269|PubMed:11170895, ECO:0000269|PubMed:11170896, ECO:0000269|PubMed:12020532, ECO:0000269|PubMed:14978182, ECO:0000269|PubMed:16612335, ECO:0000269|PubMed:9312129}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hemolytic uremic syndrome atypical 1 (AHUS1) [MIM:235400]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. {ECO:0000269|PubMed:10577907, ECO:0000269|PubMed:10762557, ECO:0000269|PubMed:11851332, ECO:0000269|PubMed:12960213, ECO:0000269|PubMed:14583443, ECO:0000269|PubMed:14978182, ECO:0000269|PubMed:20513133, ECO:0000269|PubMed:9551389}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype.; DISEASE: Macular degeneration, age-related, 4 (ARMD4) [MIM:610698]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. {ECO:0000269|PubMed:22019782}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; 	0.10048	0.13588	0.519883383	80.37272942	1002.72313	6.09993	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	9	chr1	196709736	chr1:196709736	C	CT	62	PASS	AN=2;DP=9	GT	1/0
chr1	200143152	200143152	C	G	exonic	NR5A2	.	synonymous SNV	NR5A2:NM_001276464:exon7:c.C1224G:p.A408A,NR5A2:NM_003822:exon7:c.C1302G:p.A434A,NR5A2:NM_205860:exon8:c.C1440G:p.A480A	0.959085111	0.040914105	7.84E-07	.	0.92242	0.40488	-0.291981272	33.20358575	139.12538	2.57057	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	99	chr1	200143152	chr1:200143152	C	G	69	PASS	AN=2;DP=99	GT	0/1
chr1	204124976	204124976	G	A	exonic	REN	.	nonsynonymous SNV	REN:NM_000537:exon9:c.C1031T:p.T344M	0.006604139	0.989476399	0.003919462	DISEASE: Renal tubular dysgenesis (RTD) [MIM:267430]: Autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). {ECO:0000269|PubMed:16116425}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Familial juvenile hyperuricemic nephropathy 2 (HNFJ2) [MIM:613092]: A renal disease characterized by juvenile onset of hyperuricemia, slowly progressive renal failure and anemia. {ECO:0000269|PubMed:19664745}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.09012	0.89087	-0.402212257	26.7338995	42.28384	1.23092	0.01	0.564	D	1.0	0.899	D	0.987	0.759	D	0.000	0.504	D	0.999	0.465	D	3.485	0.928	M	0.27	0.592	T	-3.03	0.627	D	0.281	0.340	0.099	0.842	D	0.486	0.804	T	0.062	0.686	D	5.810	0.795	27.2	0.999	0.963	0.925	0.556	D	c	0.474	0.285	1.000	0.747	0.497	0.185	0	3.32	0.370	1.506	0.351	0.902	0.416	0.089	0.223	0.818	0.342	11.616	0.502	Aspartic peptidase domain|Peptidase family A1 domain	.	.	0.5	65	106	chr1	204124976	chr1:204124976	G	A	65	PASS	AN=2;DP=106	GT	0/1
chr1	204192747	204192747	G	A	intronic	PLEKHA6	.	.	.	0.98196907	0.018030926	4.22E-09	.	0.21929	0.11756	-1.207107349	5.726586459	192.56504	3.00941	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	200	chr1	204192747	chr1:204192747	G	A	58	PASS	AN=2;DP=200	GT	0/1
chr1	205028152	205028152	-	C	intronic	CNTN2	.	.	.	0.129621135	0.870378534	3.31E-07	DISEASE: Epilepsy, familial adult myoclonic, 5 (FAME5) [MIM:615400]: A form of cortical myoclonic tremor with epilepsy, a syndrome characterized by cortical myoclonus and variable occurrence of epileptic seizures. Usually, myoclonic tremor is the presenting symptom, characterized by tremulous finger movements and myoclonic jerks of the limbs increased by action and posture. In a minority of patients, seizures are the presenting symptom; both complex partial as well as generalized tonic clonic seizures are described. Some patients exhibit mild cognitive impairment. {ECO:0000269|PubMed:23518707}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.39019	0.18821	-0.189246284	39.30761972	2533.66697	9.38949	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	126	33	chr1	205028152	chr1:205028152	A	AC	126	PASS	AN=2;DP=33	GT	1/0
chr1	206566861	206566861	A	-	ncRNA_intronic	SRGAP2D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	77	30	chr1	206566860	chr1:206566860	TA	T	77	PASS	AN=2;DP=30	GT	0/1
chr1	232098999	232098999	-	T	ncRNA_intronic	TSNAX-DISC1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	13	chr1	232098999	chr1:232098999	A	AT	42	PASS	AN=2;DP=13	GT	0/1
chr2	9593028	9593028	T	-	intronic	CPSF3	.	.	.	3.46E-05	0.99741028	0.002555149	.	0.16707	.	-0.558357437	19.54470394	35.81924	1.07713	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	22	chr2	9593027	chr2:9593027	AT	A	42	PASS	AN=2;DP=22	GT	0/1
chr2	13554948	13554948	G	T	intergenic	LOC100506474;LINC00276	dist=407810;dist=814050	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	47	chr2	13554948	chr2:13554948	G	T	42	PASS	AN=2;DP=47	GT	0/1
chr2	15536509	15536509	-	A	intronic	NBAS	.	.	.	1.89E-25	0.999906723	9.33E-05	DISEASE: Infantile liver failure syndrome 2 (ILFS2) [MIM:616483]: A form of infantile liver failure syndrome, a life-threatening disorder of hepatic function that manifests with acute liver failure in the first few months of life. Clinical features include anemia, renal tubulopathy, developmental delay, seizures, failure to thrive, and liver steatosis and fibrosis. {ECO:0000269|PubMed:26073778}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=NBAS mutations have been found in a multisystem disease affecting the liver, eye, immune system, connective tissue, and bone. Clinical manifestations include a progeroid appearance, short stature, slender bones, epiphyseal dysplasia with multiple phalangeal pseudo-epiphyses, cervical instability, myelopathy, elevated transaminases, hypogammaglobulinemia, reduced natural killer cells, Pelger-Huet anomaly of granulocytes, and in some cases retinal dystrophy and optic atrophy. {ECO:0000269|PubMed:26286438}.; 	.	.	-0.224542487	37.33191791	2659.86206	9.69933	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	15	chr2	15536509	chr2:15536509	G	GA	40	PASS	AN=2;DP=15	GT	0/1
chr2	27878243	27878266	GGTGAAGCTTCAACCTCCAGGTTA	-	exonic	SUPT7L	.	nonframeshift deletion	SUPT7L:NM_001282732:exon4:c.543_566del:p.N182_P189del,SUPT7L:NM_001282729:exon5:c.948_971del:p.N317_P324del,SUPT7L:NM_001282730:exon5:c.942_965del:p.N315_P322del,SUPT7L:NM_001282731:exon5:c.942_965del:p.N315_P322del,SUPT7L:NM_014860:exon5:c.948_971del:p.N317_P324del	0.833193339	0.166095092	0.000711569	.	0.12986	0.28788	-0.137658575	43.57159707	44.29914	1.27031	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	49	chr2	27878242	chr2:27878242	TGGTGAAGCTTCAACCTCCAGGTTA	T	58	PASS	AN=2;DP=49	GT	0/1
chr2	54586126	54586126	A	C	exonic	C2orf73	.	nonsynonymous SNV	C2orf73:NM_001100396:exon4:c.A419C:p.E140A	0.000860168	0.557463099	0.441676733	.	.	.	0.617373774	83.25076669	1022.80392	6.14997	0.06	0.395	T	0.763	0.417	P	0.173	0.338	B	0.007	0.316	N	0.956	0.379	D	2.505	0.732	M	1.25	0.365	T	-2.27	0.506	N	0.268	0.452	-0.961	0.390	T	0.068	0.280	T	0.013	0.324	T	3.502	0.479	23.1	0.990	0.493	0.591	0.306	D	c	0.118	0.144	0.030	0.139	0.497	0.185	0	4.3	0.504	2.228	0.424	1.199	0.960	0.526	0.269	0.816	0.342	3.720	0.079	.	.	.	0.5	48	84	chr2	54586126	chr2:54586126	A	C	48	PASS	AN=2;DP=84	GT	0/1
chr2	55863360	55863360	-	A	UTR3	PNPT1	NM_033109:c.*11_*12insT	.	.	0.908266843	0.091733155	2.06E-09	DISEASE: Combined oxidative phosphorylation deficiency 13 (COXPD13) [MIM:614932]: A mitochondrial disorder characterized by early onset severe encephalomyopathy, dystonia, choreoathetosis, bucofacial dyskinesias and combined mitochondrial respiratory chain deficiency. Nerve conductions velocities are decreased. Levels of plasma and cerebrospinal fluid lactate are increased. {ECO:0000269|PubMed:23084291}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, autosomal recessive, 70 (DFNB70) [MIM:614934]: A form of non-syndromic deafness characterized by severe, bilateral hearing impairment with prelingual onset, resulting in inability to acquire normal speech. {ECO:0000269|PubMed:23084290}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.2306	0.0952	0.135991087	63.61759849	3768.17005	12.01066	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	29	chr2	55863360	chr2:55863360	T	TA	40	PASS	AN=2;DP=29	GT	0/1
chr2	65231063	65231063	-	T	intronic	SLC1A4	.	.	.	0.242897704	0.750367908	0.006734388	.	0.12708	0.17318	-0.111973265	45.35857514	749.9076	5.43136	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	20	chr2	65231063	chr2:65231063	G	GT	41	PASS	AN=2;DP=20	GT	0/1
chr2	70166207	70166207	-	T	UTR3	MXD1	NM_002357:c.*791_*792insT;NM_001202513:c.*791_*792insT;NM_001202514:c.*791_*792insT	.	.	0.388108481	0.601963686	0.009927833	.	0.9375	0.13242	-0.317668748	31.45789101	29.2168	0.93438	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	20	chr2	70166207	chr2:70166207	A	AT	42	PASS	AN=2;DP=20	GT	0/1
chr2	100218010	100218010	C	T	exonic	AFF3	.	nonsynonymous SNV	AFF3:NM_001025108:exon13:c.G1333A:p.G445S,AFF3:NM_002285:exon13:c.G1258A:p.G420S	0.998912591	0.001087409	4.40E-12	.	0.81091	0.1261	-1.455091209	3.886529842	210.2759	3.13007	0.919	0.023	T	0.004	0.112	B	0.004	0.093	B	0.832	0.091	N	0.700	0.334	D	-0.215	0.040	N	-0.0	0.626	T	-0.6	0.178	N	0.153	0.230	-0.898	0.482	T	0.070	0.286	T	0.029	0.518	D	1.237	0.214	11.94	0.909	0.195	0.110	0.161	N	c	-1.248	-1.118	1.000	0.428	0.554	0.246	0	-5.37	0.025	-0.234	0.090	-0.505	0.051	0.950	0.328	0.993	0.574	12.972	0.577	.	.	.	0.5	59	76	chr2	100218010	chr2:100218010	C	T	59	PASS	AN=2;DP=76	GT	0/1
chr2	101098726	101098726	-	T	intronic	NMS	.	.	.	2.78E-10	0.041912109	0.958087891	.	0.0817	0.1288	0.25917371	70.05779665	1820.09065	7.86854	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	42	chr2	101098726	chr2:101098726	C	CT	52	PASS	AN=2;DP=42	GT	0/1
chr2	101640086	101640086	-	T	intronic	TBC1D8	.	.	.	5.26E-07	0.999927627	7.18E-05	.	0.16485	0.13045	-1.006844617	8.209483369	2278.58196	8.83254	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	18	chr2	101640086	chr2:101640086	G	GT	42	PASS	AN=2;DP=18	GT	0/1
chr2	114500277	114500277	A	-	exonic	SLC35F5	.	frameshift deletion	SLC35F5:NM_001330314:exon7:c.724delT:p.C242Afs*21,SLC35F5:NM_001330315:exon7:c.742delT:p.C248Afs*21,SLC35F5:NM_001330316:exon7:c.742delT:p.C248Afs*20,SLC35F5:NM_001330317:exon7:c.724delT:p.C242Afs*3,SLC35F5:NM_025181:exon7:c.742delT:p.C248Afs*21	0.001215718	0.996927948	0.001856334	.	0.26269	0.09982	0.062575634	58.74026893	105.3262	2.22212	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	8	chr2	114500276	chr2:114500276	CA	C	47	PASS	AN=2;DP=8	GT	0/1
chr2	128462192	128462192	A	-	UTR3	WDR33	NM_018383:c.*1705delT	.	.	0.999997733	2.27E-06	2.62E-19	.	0.17172	0.11281	-0.813834387	12.05472989	577.17958	4.87117	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	32	chr2	128462191	chr2:128462191	TA	T	51	PASS	AN=2;DP=32	GT	0/1
chr2	131883311	131883311	-	T	intronic	PLEKHB2	.	.	.	3.54E-06	0.573002701	0.426993762	.	0.16785	.	-0.427900189	25.14744043	21.94762	0.73814	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	54	chr2	131883311	chr2:131883311	A	AT	53	PASS	AN=2;DP=54	GT	0/1
chr2	145027394	145027394	-	A	intronic	GTDC1	.	.	.	2.41E-10	0.07320236	0.92679764	.	0.15283	0.07494	-0.176292081	40.56381222	263.31779	3.48127	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	19.17	40	chr2	145027394	chr2:145027394	T	TA	19.17	PASS	AN=0;DP=40	GT	0/1
chr2	152695179	152695179	T	-	UTR3	CACNB4	NM_001320722:c.*454delA;NM_001145798:c.*454delA;NM_000726:c.*454delA;NM_001330115:c.*454delA;NM_001330116:c.*454delA;NM_001330114:c.*454delA;NM_001330113:c.*454delA;NM_001330117:c.*454delA;NM_001330118:c.*454delA;NM_001005747:c.*454delA;NM_001005746:c.*454delA	.	.	0.011363582	0.988273668	0.00036275	DISEASE: Juvenile myoclonic epilepsy 6 (EJM6) [MIM:607682]: A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Episodic ataxia 5 (EA5) [MIM:613855]: A disorder characterized by episodes of vertigo and ataxia that last for several hours. Interictal examination show spontaneous downbeat and gaze-evoked nystagmus, mild dysarthria and truncal ataxia. {ECO:0000269|PubMed:10762541}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.19944	0.13941	0.082802743	60.09082331	22.57919	0.75555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	23	chr2	152695178	chr2:152695178	GT	G	43	PASS	AN=2;DP=23	GT	0/1
chr2	187709406	187709406	A	-	intronic	ZSWIM2	.	.	.	5.14E-10	0.363952929	0.63604707	.	0.12176	0.09356	2.311417714	98.35456476	1579.85177	7.35626	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	75	chr2	187709405	chr2:187709405	TA	T	59	PASS	AN=2;DP=75	GT	0/1
chr2	192818559	192818560	CA	-	exonic	TMEFF2	.	stopgain	TMEFF2:NM_001305134:exon9:c.873_874del:p.C291fs*0,TMEFF2:NM_016192:exon9:c.873_874del:p.C291fs*0	0.386319162	0.61325271	0.000428128	.	0.36998	0.26214	-0.139478553	43.29440906	116.63956	2.34915	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	56	61	chr2	192818558	chr2:192818558	TCA	T	56	PASS	AN=2;DP=61	GT	0/1
chr2	202700456	202700456	C	T	exonic	CDK15	.	nonsynonymous SNV	CDK15:NM_001261435:exon8:c.C821T:p.A274V,CDK15:NM_001261436:exon8:c.C821T:p.A274V,CDK15:NM_139158:exon8:c.C668T:p.A223V	5.06E-13	0.02716957	0.97283043	.	0.16207	0.08286	-0.023789244	52.09365416	171.90123	2.85972	0.001	0.784	D	0.992	0.629	D	0.939	0.657	D	0.000	0.629	D	1.000	0.588	D	1.355	0.339	L	-0.2	0.661	T	-3.08	0.633	D	0.652	0.666	-0.345	0.737	T	0.366	0.727	T	0.043	0.611	D	7.235	0.946	34	0.999	0.983	0.973	0.736	D	c	0.686	0.714	1.000	0.747	0.497	0.185	0	5.62	0.857	6.105	0.710	0.935	0.490	1.000	0.715	1.000	0.888	20.02	0.975	Protein kinase domain|Protein kinase-like domain|Serine/threonine/dual specificity protein kinase, catalytic  domain	.	.	0.5	52	90	chr2	202700456	chr2:202700456	C	T	52	PASS	AN=2;DP=90	GT	0/1
chr2	203142655	203142655	T	-	intronic	NOP58	.	.	.	0.509478886	0.490487322	3.38E-05	.	.	.	-0.47017169	23.25430526	30.9563	0.97894	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	19	chr2	203142654	chr2:203142654	CT	C	59	PASS	AN=2;DP=19	GT	0/1
chr2	204354507	204354507	C	T	exonic	RAPH1	.	nonsynonymous SNV	RAPH1:NM_001329728:exon4:c.G532A:p.D178N,RAPH1:NM_203365:exon4:c.G532A:p.D178N,RAPH1:NM_213589:exon4:c.G532A:p.D178N	0.957851233	0.042148732	3.46E-08	.	0.25984	0.27016	-2.607452819	0.807973579	124.99766	2.43194	0.206	0.682	T	0.804	0.432	P	0.173	0.396	B	0.011	0.299	N	1.000	0.499	D	1.25	0.319	L	0.96	0.460	T	-1.6	0.416	N	0.047	0.043	-0.976	0.360	T	0.113	0.404	T	0.008	0.207	T	2.994	0.420	22.2	0.998	0.882	0.936	0.583	D	c	0.129	0.220	1.000	0.747	0.707	0.730	0	5.33	0.756	2.720	0.467	0.852	0.362	1.000	0.715	0.965	0.450	19.022	0.929	.	.	.	0.5	42	11	chr2	204354507	chr2:204354507	C	T	42	PASS	AN=2;DP=11	GT	0/1
chr2	238632159	238632159	-	T	intronic	LRRFIP1	.	.	.	0.36551249	0.633984856	0.000502654	.	0.11014	0.08981	0.609894095	82.95588582	1129.28257	6.41308	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	12.52	45	chr2	238632159	chr2:238632159	G	GT	12.52	PASS	AN=0;DP=45	GT	0/1
chr2	241973240	241973240	C	T	exonic	SNED1	.	nonsynonymous SNV	SNED1:NM_001080437:exon3:c.C590T:p.T197I	0.98376281	0.01623719	1.33E-10	.	0.22403	0.13286	-1.379925048	4.364236848	4194.17391	12.86144	0.02	0.496	D	0.58	0.369	P	0.272	0.382	B	.	.	.	0.950	0.265	N	2.535	0.741	M	-0.74	0.732	T	-0.88	0.238	N	0.222	0.272	-0.579	0.657	T	0.330	0.698	T	0.119	0.800	D	4.400	0.589	24.1	0.998	0.850	0.636	0.319	D	c	0.062	0.038	0.935	0.272	0.646	0.450	0	3.53	0.394	1.624	0.364	0.852	0.362	0.999	0.424	0.513	0.273	2.452	0.042	NIDO domain	.	.	0.5	50	94	chr2	241973240	chr2:241973240	C	T	50	PASS	AN=2;DP=94	GT	0/1
chr3	7620433	7620433	C	G	exonic	GRM7	.	nonsynonymous SNV	GRM7:NM_000844:exon8:c.C1840G:p.R614G,GRM7:NM_181874:exon8:c.C1840G:p.R614G	0.999169069	0.00083093	1.36E-09	.	0.68439	0.09371	-1.616692429	2.937013447	1262.73334	6.70044	0.002	0.721	D	0.953	0.764	P	0.852	0.850	P	0.000	0.843	D	1	0.810	D	3.42	0.921	M	-2.51	0.893	D	-4.83	0.809	D	0.982	0.985	0.854	0.951	D	0.856	0.952	D	0.337	0.919	D	6.731	0.919	32	0.999	0.975	0.960	0.667	D	c	0.797	0.758	1.000	0.747	0.554	0.246	0	5.93	0.959	2.671	0.463	0.935	0.490	0.993	0.376	1.000	0.888	18.918	0.925	GPCR family 3, C-terminal	.	.	0.5	79	54	chr3	7620433	chr3:7620433	C	G	79	PASS	AN=2;DP=54	GT	0/1
chr3	9786078	9786078	C	-	exonic	BRPF1	.	frameshift deletion	BRPF1:NM_001003694:exon9:c.2806delC:p.Q938Sfs*4,BRPF1:NM_001319050:exon9:c.2785delC:p.Q931Sfs*4,BRPF1:NM_004634:exon9:c.2788delC:p.Q932Sfs*4	0.999626031	0.000373969	7.98E-12	.	0.6219	0.12281	-2.25808393	1.267987733	57.40076	1.5258	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	194	chr3	9786077	chr3:9786077	GC	G	47	PASS	AN=2;DP=194	GT	0/1
chr3	38023756	38023780	GTGGGACTCATTGCCCCAAACCAGG	-	UTR3	CTDSPL	NM_005808:c.*1398_*1422delGTGGGACTCATTGCCCCAAACCAGG;NM_001008392:c.*1398_*1422delGTGGGACTCATTGCCCCAAACCAGG	.	.	0.088848186	0.870209145	0.040942669	.	0.23991	0.1515	-0.029247611	51.40363293	80.58588	1.8968	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	66	chr3	38023755	chr3:38023755	TGTGGGACTCATTGCCCCAAACCAGG	T	58	PASS	AN=2;DP=66	GT	0/1
chr3	45761125	45761128	TAAT	-	intronic	SACM1L	.	.	.	0.721901743	0.278097217	1.04E-06	.	0.55456	0.1049	-0.424258538	25.56027365	29.43851	0.94154	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	14	chr3	45761124	chr3:45761124	GTAAT	G	63	PASS	AN=2;DP=14	GT	0/1
chr3	57140083	57140083	C	A	intronic	IL17RD	.	.	.	2.64E-05	0.98202302	0.017950625	.	0.6749	0.12392	-0.172654315	40.63458363	2297.79347	8.87861	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	65	chr3	57140083	chr3:57140083	C	A	51	PASS	AN=2;DP=65	GT	0/1
chr3	119469924	119469924	C	G	exonic	MAATS1	.	nonsynonymous SNV	MAATS1:NM_001320318:exon15:c.C1906G:p.Q636E,MAATS1:NM_001320317:exon16:c.C2098G:p.Q700E,MAATS1:NM_001320316:exon17:c.C2224G:p.Q742E,MAATS1:NM_033364:exon17:c.C2284G:p.Q762E	9.78E-10	0.904945227	0.095054772	.	0.06869	0.09515	0.872633161	88.87119604	840.25979	5.67623	0.316	0.137	T	0.0	0.026	B	0.002	0.063	B	0.540	0.115	N	1	0.090	N	.	.	.	1.71	0.267	T	-0.37	0.132	N	0.029	0.115	-0.964	0.384	T	0.024	0.104	T	0.004	0.111	T	-1.774	0.011	0.002	0.649	0.074	0.073	0.132	N	c	-1.165	-1.145	0.304	0.192	0.638	0.428	0	0.059	0.136	0.546	0.228	0.841	0.343	0.000	0.063	0.002	0.062	6.517	0.213	.	.	.	0.5	59	33	chr3	119469924	chr3:119469924	C	G	59	PASS	AN=2;DP=33	GT	0/1
chr3	184552423	184552423	-	T	intronic	VPS8	.	.	.	3.62E-06	0.999996197	1.85E-07	.	0.13365	0.11078	-0.365622677	28.30856334	3238.91039	10.83959	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	32	chr3	184552422	chr3:184552422	CT	CTT,C	40	PASS	AN=2;DP=32	GT	0/1
chr3	184552423	184552423	T	-	intronic	VPS8	.	.	.	3.62E-06	0.999996197	1.85E-07	.	0.13365	0.11078	-0.365622677	28.30856334	3238.91039	10.83959	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	32	chr3	184552422	chr3:184552422	CT	CTT,C	40	PASS	AN=2;DP=32	GT	0/1
chr3	193209178	193209178	T	C	exonic	ATP13A4	.	nonsynonymous SNV	ATP13A4:NM_032279:exon6:c.A543G:p.I181M	6.08E-10	0.999598041	0.000401958	DISEASE: Note=A chromosomal aberration involving ATP13A4 is found in 2 patients with specific language impairment (SLI) disorders. Paracentric inversion inv(3)(q25;q29). The inversion produces a disruption of the protein. {ECO:0000269|PubMed:15925480}.; 	0.08132	0.09862	-1.383523256	4.358339231	5510.00677	15.30149	0.153	0.282	T	0.998	0.764	D	0.981	0.769	D	0.000	0.629	D	0.109	0.359	P	2.085	0.579	M	-1.2	0.785	T	-1.6	0.387	N	0.226	0.389	-0.935	0.434	T	0.000	0.000	T	.	.	.	4.024	0.541	23.6	0.994	0.623	0.540	0.292	D	c	0.394	0.329	0.008	0.115	0.487	0.133	0	4.63	0.570	-0.414	0.071	1.011	0.635	0.712	0.285	1.000	0.888	9.318	0.369	Cation-transporting P-type ATPase, N-terminal	ENSG00000127249.10|ENSG00000127249.10	Lung|Testis	0.5	90	15	chr3	193209178	chr3:193209178	T	C	90	PASS	AN=2;DP=15	GT	1/0
chr3	195717077	195717077	-	GCGCCAG	ncRNA_exonic	SDHAP1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	50	chr3	195717077	chr3:195717077	A	AGCGCCAG	65	PASS	AN=2;DP=50	GT	0/1
chr3	195965315	195965315	-	G	UTR3	PCYT1A	NM_001312673:c.*243_*244insC;NM_005017:c.*243_*244insC	.	.	0.098300076	0.90012567	0.001574255	DISEASE: Spondylometaphyseal dysplasia with cone-rod dystrophy (SMDCRD) [MIM:608940]: A disorder characterized by postnatal growth deficiency resulting in profound short stature, rhizomelia with bowing of the lower extremities, platyspondyly with anterior vertebral protrusions, progressive metaphyseal irregularity and cupping with shortened tubular bones, and early-onset progressive visual impairment associated with a pigmentary maculopathy and electroretinographic evidence of cone-rod dysfunction. {ECO:0000269|PubMed:24387990, ECO:0000269|PubMed:24387991}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.75481	.	-0.846787714	11.05803255	78.82184	1.87555	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	22	chr3	195965315	chr3:195965315	T	TG	45	PASS	AN=2;DP=22	GT	0/1
chr4	997905	997905	G	A	intronic	IDUA	.	.	.	2.64E-08	0.478326206	0.521673767	DISEASE: Mucopolysaccharidosis 1H (MPS1H) [MIM:607014]: A severe form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. Patients with MPS1H usually present, within the first year of life, a combination of hepatosplenomegaly, skeletal deformities, corneal clouding and severe mental retardation. Obstructive airways disease, respiratory infection and cardiac complications usually result in death before 10 years of age. {ECO:0000269|PubMed:10466419, ECO:0000269|PubMed:10735634, ECO:0000269|PubMed:12559846, ECO:0000269|PubMed:1301941, ECO:0000269|PubMed:15300847, ECO:0000269|PubMed:21394825, ECO:0000269|PubMed:7550232, ECO:0000269|PubMed:7550242, ECO:0000269|PubMed:7951228, ECO:0000269|PubMed:8019563, ECO:0000269|PubMed:8328452, ECO:0000269|PubMed:8401515, ECO:0000269|Ref.20}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mucopolysaccharidosis 1H/S (MPS1H/S) [MIM:607015]: A form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. MPS1H/S represents an intermediate phenotype of the MPS1 clinical spectrum. It is characterized by relatively little neurological involvement, but most of the somatic symptoms described for severe MPS1 develop in the early to mid-teens, causing considerable loss of mobility. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mucopolysaccharidosis 1S (MPS1S) [MIM:607016]: A mild form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. Patients with MPS1S may have little or no neurological involvement, normal stature and life span, but present development of joints stiffness, mild hepatosplenomegaly, aortic valve disease and corneal clouding. {ECO:0000269|PubMed:12559846, ECO:0000269|PubMed:15300847, ECO:0000269|PubMed:19396826, ECO:0000269|PubMed:21394825, ECO:0000269|PubMed:25256405, ECO:0000269|PubMed:7550232, ECO:0000269|PubMed:7550242, ECO:0000269|PubMed:8213840}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.08409	0.09876	.	.	2688.19258	9.75774	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	98	chr4	997905	chr4:997905	G	A	58	PASS	AN=2;DP=98	GT	0/1
chr4	15989410	15989410	C	T	intronic	PROM1	.	.	.	7.17E-17	0.027832798	0.972167202	DISEASE: Retinitis pigmentosa 41 (RP41) [MIM:612095]: A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. {ECO:0000269|PubMed:10587575, ECO:0000269|PubMed:17605048}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cone-rod dystrophy 12 (CORD12) [MIM:612657]: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Stargardt disease 4 (STGD4) [MIM:603786]: A common hereditary macular degeneration. It is characterized by decreased central vision, atrophy of the macula and underlying retinal pigment epithelium, and frequent presence of prominent flecks in the posterior pole of the retina. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Retinal macular dystrophy 2 (MCDR2) [MIM:608051]: A bull's-eye macular dystrophy characterized by bilateral annular atrophy of retinal pigment epithelium at the macula. {ECO:0000269|PubMed:18654668}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31674	0.31496	-1.368693559	4.482189196	96.86296	2.12686	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	43	42	chr4	15989410	chr4:15989410	C	T	43	PASS	AN=2;DP=42	GT	0/1
chr4	46725760	46725760	-	T	intergenic	GABRA2;COX7B2	dist=333675;dist=11087	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	59	chr4	46725760	chr4:46725760	G	GT	42	PASS	AN=2;DP=59	GT	0/1
chr4	80957196	80957196	A	-	intronic	ANTXR2	.	.	.	0.405188748	0.594440676	0.000370576	DISEASE: Hyaline fibromatosis syndrome (HFS) [MIM:228600]: An autosomal recessive syndrome characterized by abnormal growth of hyalinized fibrous tissue usually affecting subcutaneous regions on the scalp, ears, neck, face, hands, and feet. The lesions appear as pearly papules or fleshy nodules. Additional features include gingival hypertrophy, progressive joint contractures resulting in severe limitation of mobility, osteopenia, and osteoporosis. Disease severity is variable. Some individuals manifest symptoms in infancy and have additional visceral or systemic involvement. Hyaline deposits in multiple organs, recurrent infections and intractable diarrhea often lead to early death. Surviving children may suffer from severely reduced mobility due to joint contractures. Other patients have later onset of a milder disorder affecting only the face and digits. {ECO:0000269|PubMed:12973667, ECO:0000269|PubMed:14508707, ECO:0000269|PubMed:15725249}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.29739	0.10893	0.573279816	82.08303845	200.14281	3.05718	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	67	40	chr4	80957195	chr4:80957195	GA	G	67	PASS	AN=2;DP=40	GT	0/1
chr4	89345663	89345663	A	-	intronic	HERC6	.	.	.	3.19E-09	0.91230323	0.087696767	.	0.09058	0.08047	1.938319883	97.51120547	1555.21394	7.30701	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	48	20	chr4	89345662	chr4:89345662	CA	C	48	PASS	AN=2;DP=20	GT	0/1
chr4	100009836	100009836	C	A	intronic	ADH5	.	.	.	9.11E-07	0.313157521	0.686841567	.	0.26363	0.34407	0.193034296	66.82000472	62.29801	1.61087	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	258	chr4	100009836	chr4:100009836	C	A	58	PASS	AN=2;DP=258	GT	0/1
chr4	113178967	113178967	A	-	intronic	AP1AR	.	.	.	0.511166929	0.488021686	0.000811385	.	0.14777	0.14109	0.327131069	73.27199811	63.26348	1.62796	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	47	chr4	113178966	chr4:113178966	TA	T	58	PASS	AN=2;DP=47	GT	0/1
chr4	151683004	151683004	A	-	intronic	LRBA	.	.	.	0.044229437	0.955770563	1.54E-17	DISEASE: Immunodeficiency, common variable, 8, with autoimmunity (CVID8) [MIM:614700]: An autosomal recessive immunologic disorder associated with defective B-cell differentiation and decreased or absent antibody production. Affected individuals have early- childhood onset of recurrent infections, particularly respiratory infections, and also develop variable autoimmune disorders, including idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and inflammatory bowel disease. {ECO:0000269|PubMed:22608502}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.31593	.	-2.513092117	0.925925926	4753.32179	13.94798	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	39	chr4	151683003	chr4:151683003	TA	T	58	PASS	AN=2;DP=39	GT	0/1
chr4	152025695	152025695	A	-	exonic	RPS3A	.	frameshift deletion	RPS3A:NM_001006:exon6:c.745delA:p.V250Lfs*24	0.744269731	0.253389263	0.002341006	.	0.99653	0.30163	0.013025609	54.62962963	4.49164	0.16244	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	130	chr4	152025694	chr4:152025694	TA	T	58	PASS	AN=2;DP=130	GT	0/1
chr5	10390429	10390429	T	-	intronic	MARCH6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	32	chr5	10390428	chr5:10390428	CT	C	47	PASS	AN=2;DP=32	GT	0/1
chr5	40798154	40798154	G	T	intronic	PRKAA1	.	.	.	0.035101034	0.96325073	0.001648236	.	0.90852	0.13068	-0.494039303	22.09247464	21.33891	0.72054	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	277	chr5	40798154	chr5:40798154	G	T	62	PASS	AN=2;DP=277	GT	0/1
chr5	54528179	54528179	C	T	intronic	CCNO	.	.	.	0.040710125	0.843060511	0.116229364	DISEASE: Ciliary dyskinesia, primary, 29 (CILD29) [MIM:615872]: A disorder characterized by abnormalities of motile cilia. Respiratory infections leading to chronic inflammation and bronchiectasis are recurrent, due to defects in the respiratory cilia. CILD29 patients do not exhibit situs inversus, a congenital abnormality in which visceral organs are opposite to their normal positions (situs solitus) due to lateral transposition. {ECO:0000269|PubMed:24747639}. Note=The disease is caused by mutations affecting the gene represented in this entry. Marked reduction of cilia in multiciliate cells due to defective mother centriole generation and placement. Remaining cilia correctly express axonemal motor proteins, are motile and do not show beating defects. Defects are probably caused by a strong reduction in the number of multiple motile cilia covering the cell surface in respiratory epithelial cells (PubMed:24747639). {ECO:0000269|PubMed:24747639}.; 	0.08032	0.19498	0.483275131	79.25218212	97.40203	2.13267	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	92	113	chr5	54528179	chr5:54528179	C	T	92	PASS	AN=2;DP=113	GT	0/1
chr5	115168370	115168370	A	G	intronic	ATG12	.	.	.	0.001658071	0.699322448	0.299019481	.	0.10345	0.10587	0.147123112	64.11299835	58.06341	1.54097	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr5	115168370	chr5:115168370	A	G	.	PASS	AN=0;DP=27	GT	0/1
chr5	122139264	122139264	A	G	exonic	SNX2	.	nonsynonymous SNV	SNX2:NM_001278199:exon6:c.A248G:p.H83R,SNX2:NM_003100:exon6:c.A599G:p.H200R	0.997941242	0.002058746	1.25E-08	.	0.339	0.13169	-0.692458599	14.96815287	25.76147	0.83932	1.0	0.085	T	0.001	0.067	B	0.01	0.139	B	0.000	0.629	D	1.000	0.588	D	1.005	0.253	L	1.29	0.358	T	-1.11	0.383	N	0.464	0.519	-1.076	0.082	T	0.050	0.213	T	0.012	0.306	T	0.454	0.138	7.070	0.927	0.217	0.983	0.817	D	c	-0.333	-0.115	0.988	0.315	0.732	0.924	0	4.38	0.519	7.334	0.783	1.028	0.649	1.000	0.715	0.999	0.750	11.303	0.484	Phox homologous domain;Sorting nexin, N-terminal	.	.	0.5	74	47	chr5	122139264	chr5:122139264	A	G	74	PASS	AN=2;DP=47	GT	0/1
chr5	130727893	130727893	G	A	UTR3	CDC42SE2	NM_020240:c.*300G>A;NM_001038702:c.*300G>A	.	.	0.753728627	0.236652022	0.009619351	.	0.27557	0.12378	-0.09720619	46.20193442	1.83486	0.05767	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	26	chr5	130727893	chr5:130727893	G	A	.	PASS	AN=0;DP=26	GT	0/1
chr5	145508515	145508515	-	A	intronic	LARS	.	.	.	2.27E-05	0.999976973	3.23E-07	DISEASE: Infantile liver failure syndrome 1 (ILFS1) [MIM:615438]: A life-threatening disorder of hepatic function that manifests with acute liver failure in the first few months of life. Clinical features include anemia, renal tubulopathy, developmental delay, seizures, failure to thrive, and liver steatosis and fibrosis. {ECO:0000269|PubMed:22607940}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.76027	.	-0.437212558	24.67563105	3699.75044	11.85134	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	13	chr5	145508515	chr5:145508515	T	TA	50	PASS	AN=2;DP=13	GT	0/1
chr5	147504305	147504305	-	T	intronic	SPINK5	.	.	.	2.12E-17	0.920781311	0.079218689	DISEASE: Netherton syndrome (NETH) [MIM:256500]: An autosomal recessive congenital ichthyosis associated with hair shaft abnormalities and anomalies of the immune system. Typical features are ichthyosis linearis circumflexa, ichthyosiform erythroderma, trichorrhexis invaginata (bamboo hair), atopic dermatitis, and hayfever. High postnatal mortality is due to failure to thrive, infections and hypernatremic dehydration. {ECO:0000269|PubMed:10835624}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.2529	0.29285	2.831581484	99.08586931	18873.47781	29.29597	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	63	81	chr5	147504305	chr5:147504305	C	CT	63	PASS	AN=2;DP=81	GT	0/1
chr5	150646278	150646278	T	-	intronic	GM2A	.	.	.	0.111186455	0.777402352	0.111411193	DISEASE: GM2-gangliosidosis AB (GM2GAB) [MIM:272750]: An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B. {ECO:0000269|PubMed:1915858, ECO:0000269|PubMed:8244332, ECO:0000269|PubMed:8900233}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.26723	0.19354	0.681699246	84.93158764	326.06898	3.83913	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	224	chr5	150646277	chr5:150646277	AT	A	53	PASS	AN=2;DP=224	GT	0/1
chr5	156945760	156945760	G	A	intronic	ADAM19	.	.	.	4.20E-06	0.999906953	8.88E-05	.	0.71514	0.13137	0.918552705	89.5730125	5188.76456	14.82439	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	124	chr5	156945760	chr5:156945760	G	A	58	PASS	AN=2;DP=124	GT	0/1
chr5	176759027	176759027	-	A	UTR3	LMAN2	NM_006816:c.*59_*60insT	.	.	0.0500443	0.927871421	0.022084279	.	0.12943	0.14229	-0.754958418	13.57631517	88.77601	2.02091	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	72	83	chr5	176759027	chr5:176759027	T	TA	72	PASS	AN=2;DP=83	GT	0/1
chr5	177987758	177987758	-	A	intronic	COL23A1	.	.	.	9.57E-10	0.90264393	0.097356069	.	0.07258	0.08141	0.75875178	86.82472281	1444.11081	7.08807	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	65	47	chr5	177987758	chr5:177987758	G	GA	65	PASS	AN=2;DP=47	GT	0/1
chr5	179150789	179150789	T	-	intronic	CANX	.	.	.	0.86247386	0.137522598	3.54E-06	.	0.78419	0.89499	-0.159704656	41.90846898	163.62404	2.79331	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	40	chr5	179150788	chr5:179150788	GT	G,GTT	55	PASS	AN=2;DP=40	GT	0/1
chr5	179150789	179150789	-	T	intronic	CANX	.	.	.	0.86247386	0.137522598	3.54E-06	.	0.78419	0.89499	-0.159704656	41.90846898	163.62404	2.79331	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	55	40	chr5	179150788	chr5:179150788	GT	G,GTT	55	PASS	AN=2;DP=40	GT	0/1
chr6	10410424	10410424	G	A	exonic	TFAP2A	.	nonsynonymous SNV	TFAP2A:NM_001032280:exon2:c.C172T:p.P58S,TFAP2A:NM_001042425:exon2:c.C178T:p.P60S,TFAP2A:NM_003220:exon2:c.C190T:p.P64S	0.987223276	0.012771396	5.33E-06	DISEASE: Branchiooculofacial syndrome (BOFS) [MIM:113620]: A syndrome characterized by growth retardation, bilateral branchial sinus defects with hemangiomatous, scarred skin, cleft lip with or without cleft palate, pseudocleft of the upper lip, nasolacrimal duct obstruction, low set ears with posterior rotation, a malformed, asymmetrical nose with a broad bridge and flattened tip, conductive or sensorineural deafness, ocular and renal anomalies. {ECO:0000269|PubMed:18423521}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.96726	0.95367	-0.427900189	25.14744043	13.97787	0.50725	0.01	0.574	D	0.911	0.899	P	0.433	0.916	B	0.000	0.843	D	1	0.810	D	1.73	0.448	L	-1.43	0.807	T	-3.81	0.795	D	0.582	0.618	0.042	0.831	D	0.497	0.810	T	0.281	0.903	D	4.324	0.579	24.0	0.999	0.972	0.996	0.982	D	c	0.601	0.576	1.000	0.747	0.447	0.083	0	3.8	0.427	9.982	0.992	0.902	0.416	1.000	0.715	1.000	0.888	12.724	0.564	.	.	.	0.5	67	284	chr6	10410424	chr6:10410424	G	A	67	PASS	AN=2;DP=284	GT	0/1
chr6	17779922	17779922	-	A	intronic	KIF13A	.	.	.	0.999958506	4.15E-05	5.23E-19	.	0.14914	0.13297	-0.093786226	46.49681529	493.50968	4.56777	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	13.3	57	chr6	17779922	chr6:17779922	G	GA	13.3	PASS	AN=0;DP=57	GT	0/1
chr6	73951959	73951959	C	T	exonic	KHDC1	.	synonymous SNV	KHDC1:NM_030568:exon3:c.G114A:p.G38G,KHDC1:NM_001251874:exon4:c.G333A:p.G111G	6.80E-05	0.49146714	0.508464847	.	0.09427	.	0.038710339	56.92380278	694.65301	5.25432	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	31	chr6	73951959	chr6:73951959	C	T	.	PASS	AN=0;DP=31	GT	0/1
chr6	80194766	80194766	-	A	UTR3	LCA5	NM_181714:c.*1954_*1955insT;NM_001122769:c.*1954_*1955insT	.	.	0.004282174	0.994223193	0.001494632	DISEASE: Leber congenital amaurosis 5 (LCA5) [MIM:604537]: A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus. {ECO:0000269|PubMed:17546029, ECO:0000269|PubMed:18000884, ECO:0000269|PubMed:18334959}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.1667	0.11088	-0.130380821	44.03161123	3626.18224	11.68454	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	41	chr6	80194766	chr6:80194766	G	GA	60	PASS	AN=2;DP=41	GT	0/1
chr6	108214754	108214754	-	T	exonic	SEC63	.	frameshift insertion	SEC63:NM_007214:exon16:c.1605dupA:p.P536Tfs*23	1.24E-05	0.999895028	9.25E-05	.	0.26756	0.15588	-0.578583623	18.71903751	221.36898	3.21909	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	10.12	32	chr6	108214754	chr6:108214754	G	GT	10.12	PASS	AN=0;DP=32	GT	0/1
chr6	134212873	134212873	G	A	exonic	TCF21	.	nonsynonymous SNV	TCF21:NM_003206:exon2:c.G473A:p.G158E,TCF21:NM_198392:exon2:c.G473A:p.G158E	0.805369944	0.189537108	0.005092948	.	0.50048	0.24689	0.25917371	70.05779665	477.84739	4.51344	0.002	0.721	D	0.734	0.408	P	0.221	0.361	B	0.000	0.843	D	1	0.810	D	1.245	0.315	L	-4.05	0.965	D	-1.86	0.435	N	0.71	0.749	0.696	0.931	D	0.773	0.923	D	0.120	0.801	D	4.852	0.651	24.8	0.996	0.725	0.926	0.559	D	c	0.444	0.545	1.000	0.747	0.598	0.340	0	5.63	0.861	6.582	0.738	1.048	0.713	1.000	0.715	0.995	0.604	19.674	0.959	.	.	.	0.5	67	137	chr6	134212873	chr6:134212873	G	A	67	PASS	AN=2;DP=137	GT	0/1
chr6	158049415	158049415	C	G	exonic	ZDHHC14	.	nonsynonymous SNV	ZDHHC14:NM_024630:exon4:c.C600G:p.N200K,ZDHHC14:NM_153746:exon4:c.C600G:p.N200K	0.982366558	0.01763106	2.38E-06	.	.	0.10652	0.350995466	74.37485256	67.03988	1.69272	0.001	0.912	D	1.0	0.899	D	0.995	0.971	D	0.000	0.843	D	1	0.810	D	3.71	0.948	H	1.72	0.266	T	-5.84	0.884	D	0.488	0.535	-0.374	0.729	T	0.221	0.584	T	0.072	0.714	D	6.510	0.897	31	0.998	0.908	0.972	0.734	D	c	0.872	0.798	1.000	0.747	0.706	0.609	0	5.56	0.836	5.746	0.681	0.935	0.490	1.000	0.715	1.000	0.888	19.535	0.952	Zinc finger, DHHC-type, palmitoyltransferase	.	.	0.5	44	44	chr6	158049415	chr6:158049415	C	G	44	PASS	AN=2;DP=44	GT	0/1
chr6	161121626	161121626	C	T	intergenic	LPA;PLG	dist=34219;dist=1599	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr6	161121626	chr6:161121626	C	T	.	PASS	AN=0;DP=45	GT	0/1
chr7	5413785	5413785	C	T	exonic	TNRC18	.	nonsynonymous SNV	TNRC18:NM_001080495:exon10:c.G3130A:p.G1044S	0.999973966	2.60E-05	1.21E-14	.	.	.	.	.	6309.78902	16.61915	0.392	0.108	T	0.028	0.184	B	0.011	0.145	B	.	.	.	1	0.090	N	-0.345	0.033	N	2.83	0.108	T	-0.47	0.152	N	0.079	0.071	-0.972	0.367	T	0.024	0.104	T	0.029	0.520	D	0.713	0.162	8.912	0.820	0.135	0.648	0.323	D	c	-0.699	-0.672	0.004	0.103	0.563	0.310	0	3.95	0.448	1.903	0.393	0.887	0.390	0.930	0.320	0.030	0.147	8.998	0.350	.	.	.	0.5	.	165	chr7	5413785	chr7:5413785	C	T	.	PASS	AN=0;DP=165	GT	0/1
chr7	5460674	5460674	C	T	intronic	TNRC18	.	.	.	0.999973966	2.60E-05	1.21E-14	.	.	.	.	.	6309.78902	16.61915	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	207	chr7	5460674	chr7:5460674	C	T	59	PASS	AN=2;DP=207	GT	0/1
chr7	5873281	5873281	T	C	ncRNA_intronic	ZNF815P	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	37	chr7	5873281	chr7:5873281	T	C	.	PASS	AN=0;DP=37	GT	0/1
chr7	15347150	15347150	-	T	intronic	AGMO	.	.	.	3.26E-07	0.774065266	0.225934409	.	0.05711	0.12273	0.402364592	76.45081387	546.90919	4.75481	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	68	chr7	15347150	chr7:15347150	G	GT	53	PASS	AN=2;DP=68	GT	0/1
chr7	29874354	29874354	C	T	exonic	WIPF3	.	nonsynonymous SNV	WIPF3:NM_001080529:exon2:c.C14T:p.P5L	0.000296999	0.799391174	0.200311827	.	0.16204	.	.	.	274.86842	3.55213	0.0	0.912	D	1.0	0.899	D	0.995	0.818	D	.	.	.	0.999	0.467	D	0.895	0.225	L	-0.98	0.759	T	-3.12	0.637	D	0.637	0.668	-0.087	0.804	T	0.457	0.789	T	0.070	0.709	D	5.556	0.755	26.4	0.944	0.241	0.635	0.318	D	c	0.498	0.465	0.912	0.264	0.615	0.372	0	4.63	0.570	3.112	0.498	0.935	0.490	0.659	0.280	0.952	0.428	13.153	0.587	.	.	.	0.5	64	346	chr7	29874354	chr7:29874354	C	T	64	PASS	AN=2;DP=346	GT	0/1
chr7	70229846	70229846	G	T	exonic	AUTS2	.	synonymous SNV	AUTS2:NM_001127231:exon8:c.G1323T:p.L441L,AUTS2:NM_015570:exon8:c.G1323T:p.L441L	0.996187482	0.003812518	9.39E-11	.	0.83083	0.1075	-1.967739992	1.816466148	320.02805	3.80007	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	226	chr7	70229846	chr7:70229846	G	T	74	PASS	AN=2;DP=226	GT	0/1
chr7	76610356	76610356	C	-	ncRNA_exonic	DTX2P1-UPK3BP1-PMS2P11	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	94	309	chr7	76610355	chr7:76610355	AC	A	94	PASS	AN=2;DP=309	GT	0/1
chr7	76991911	76991911	T	-	exonic	GSAP	.	frameshift deletion	GSAP:NM_001350900:exon11:c.293delA:p.Y98Sfs*20,GSAP:NM_001350901:exon11:c.293delA:p.Y98Sfs*20,GSAP:NM_001350898:exon12:c.881delA:p.Y294Sfs*20,GSAP:NM_001350896:exon13:c.938delA:p.Y313Sfs*20,GSAP:NM_001350897:exon13:c.938delA:p.Y313Sfs*20,GSAP:NM_001350899:exon13:c.938delA:p.Y313Sfs*20,GSAP:NM_017439:exon13:c.938delA:p.Y313Sfs*20	3.60E-16	0.241435267	0.758564733	.	.	.	0.268267497	70.64166077	2346.20682	8.97223	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	20	chr7	76991910	chr7:76991910	GT	G	59	PASS	AN=2;DP=20	GT	0/1
chr7	87323209	87323209	-	T	intronic	ABCB1;RUNDC3B	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	19	chr7	87323209	chr7:87323209	A	AT	42	PASS	AN=2;DP=19	GT	0/1
chr7	91706301	91706301	C	T	exonic	AKAP9	.	stopgain	AKAP9:NM_005751:exon29:c.C6745T:p.Q2249X,AKAP9:NM_147185:exon29:c.C6721T:p.Q2241X	2.29E-05	0.999977065	4.21E-21	DISEASE: Long QT syndrome 11 (LQT11) [MIM:611820]: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. {ECO:0000269|PubMed:18093912}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.14649	0.1106	0.223857359	68.44774711	6014.5693	16.20152	.	.	.	.	.	.	.	.	.	0.005	0.334	N	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	13.728	0.993	43	0.997	0.828	0.967	0.703	D	c	1.114	0.980	1.000	0.517	0.732	0.924	0	5.59	0.846	4.468	0.597	0.852	0.362	1.000	0.715	0.982	0.498	19.956	0.972	.	.	.	0.5	58	82	chr7	91706301	chr7:91706301	C	T	58	PASS	AN=2;DP=82	GT	0/1
chr7	94285912	94285912	-	T	intronic	PEG10	.	.	.	0.894178858	0.10478651	0.001034632	.	0.70725	0.10969	-0.273576253	33.97027601	11.52995	0.4171	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	68	63	chr7	94285912	chr7:94285912	G	GT	68	PASS	AN=2;DP=63	GT	0/1
chr7	98639905	98639905	T	-	intronic	SMURF1	.	.	.	0.996803391	0.003196608	3.02E-10	.	0.34495	0.16861	-1.375949569	4.393724935	20.01889	0.68296	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	14	chr7	98639904	chr7:98639904	AT	A	62	PASS	AN=2;DP=14	GT	0/1
chr7	130037270	130037270	C	T	UTR3	CEP41	NM_001257158:c.*1462G>A;NM_001257159:c.*1462G>A;NM_018718:c.*1462G>A	.	.	0.000125629	0.956230668	0.043643703	DISEASE: Joubert syndrome 15 (JBTS15) [MIM:614464]: An autosomal recessive disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy, renal disease, liver fibrosis and polydactyly. {ECO:0000269|PubMed:22246503}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Genetic variations in CEP41 may be associated with susceptibility to autism (PubMed:21438139). {ECO:0000269|PubMed:21438139}.; 	0.35352	0.12266	0.551232944	81.48148148	110.55518	2.28931	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	25	chr7	130037270	chr7:130037270	C	T	.	PASS	AN=0;DP=25	GT	0/1
chr7	137782541	137782541	C	A	intronic	AKR1D1	.	.	.	5.69E-08	0.23677999	0.763219953	.	0.1437	0.16811	-0.648365105	16.35999056	21.07566	0.71321	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	35	chr7	137782541	chr7:137782541	C	A	52	PASS	AN=2;DP=35	GT	0/1
chr8	37968324	37968324	T	G	exonic	ASH2L	.	nonsynonymous SNV	ASH2L:NM_001282272:exon4:c.T141G:p.H47Q,ASH2L:NM_001105214:exon5:c.T276G:p.H92Q,ASH2L:NM_001261832:exon5:c.T276G:p.H92Q,ASH2L:NM_004674:exon5:c.T558G:p.H186Q	0.995792116	0.00420787	1.44E-08	.	0.14146	0.11705	-0.26993514	34.59542345	107.32611	2.24775	0.68	0.682	T	0.012	0.561	B	0.006	0.572	B	0.000	0.843	D	1	0.810	D	1.59	0.404	L	1.87	0.241	T	-0.4	0.247	N	0.736	0.790	-1.071	0.091	T	0.081	0.320	T	0.019	0.414	T	1.274	0.218	12.14	0.847	0.150	0.915	0.533	D	c	-0.183	-0.140	0.992	0.325	0.719	0.830	0	2.34	0.279	0.209	0.171	0.890	0.394	0.991	0.370	0.994	0.587	8.795	0.338	.	.	.	0.5	47	30	chr8	37968324	chr8:37968324	T	G	47	PASS	AN=2;DP=30	GT	0/1
chr8	85833388	85833388	-	T	UTR3	RALYL	NM_001100393:c.*242_*243insT;NM_001100392:c.*242_*243insT;NM_001287243:c.*242_*243insT;NM_173848:c.*242_*243insT;NM_001100391:c.*242_*243insT;NM_001287244:c.*242_*243insT	.	.	0.029690036	0.924042635	0.046267328	.	0.21161	0.11262	-0.271755481	34.31823543	33.66101	1.03832	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	22	chr8	85833388	chr8:85833388	G	GT	42	PASS	AN=2;DP=22	GT	0/1
chr8	95444348	95444348	-	A	UTR3	FSBP;RAD54B	NM_001256141:c.*10_*11insT;NM_001205262:c.*486_*487insT	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	13	chr8	95444348	chr8:95444348	G	GA	52	PASS	AN=2;DP=13	GT	0/1
chr9	33794798	33794799	GA	-	exonic	PRSS3	.	frameshift deletion	PRSS3:NM_001197097:exon2:c.9_10del:p.E5Dfs*27	4.80E-10	0.015739826	0.984260174	.	0.28887	0.8505	-0.139478553	43.29440906	1149.53078	6.46	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	16	chr9	33794797	chr9:33794797	TGA	T	60	PASS	AN=2;DP=16	GT	0/1
chr9	79318365	79318365	C	A	exonic	PRUNE2	.	stopgain	PRUNE2:NM_001308047:exon9:c.G8164T:p.E2722X,PRUNE2:NM_001308048:exon9:c.G8164T:p.E2722X,PRUNE2:NM_015225:exon9:c.G8164T:p.E2722X	3.68E-12	0.999991467	8.53E-06	.	0.07279	0.07799	2.779178029	99.02689314	10480.06134	22.38246	.	.	.	.	.	.	.	.	.	0.001	0.407	D	1	0.810	A	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	14.257	0.996	45	0.997	0.791	0.926	0.558	D	c	0.998	0.846	1.000	0.747	0.615	0.372	0	5.71	0.890	1.226	0.320	0.892	0.403	1.000	0.715	1.000	0.888	13.305	0.596	.	.	.	0.5	65	57	chr9	79318365	chr9:79318365	C	A	65	PASS	AN=2;DP=57	GT	0/1
chr9	85607951	85607951	-	A	intronic	RASEF	.	.	.	3.27E-05	0.999404853	0.000562435	.	0.09812	.	0.42259095	77.22929936	665.99098	5.16516	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	19	chr9	85607951	chr9:85607951	G	GA	40	PASS	AN=2;DP=19	GT	0/1
chr9	100618882	100618900	GGTTCAGTCCAAATGGGGA	-	UTR3	FOXE1	NM_004473:c.*1564_*1582delGGTTCAGTCCAAATGGGGA	.	.	.	.	.	DISEASE: Bamforth-Lazarus syndrome (BLS) [MIM:241850]: A disease characterized by thyroid agenesis, cleft palate and choanal atresia. {ECO:0000269|PubMed:12165566, ECO:0000269|PubMed:9697705}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	.	0.10592	.	.	82.34677	1.92681	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	25	chr9	100618881	chr9:100618881	TGGTTCAGTCCAAATGGGGA	T	84	PASS	AN=2;DP=25	GT	0/1
chr9	103275550	103275550	G	A	intronic	MSANTD3-TMEFF1;TMEFF1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	91	chr9	103275550	chr9:103275550	G	A	54	PASS	AN=2;DP=91	GT	0/1
chr9	119199765	119199765	G	A	intronic	ASTN2	.	.	.	0.989172284	0.010827716	2.44E-10	.	0.28632	0.11008	-2.271160931	1.256192498	1146.31095	6.45411	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	80	145	chr9	119199765	chr9:119199765	G	A	80	PASS	AN=2;DP=145	GT	0/1
chr9	127032348	127032348	-	C	intronic	NEK6	.	.	.	0.644137661	0.35559309	0.000269249	.	0.12306	0.11384	-0.359940251	28.93371078	287.30993	3.63133	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	91	65	chr9	127032348	chr9:127032348	G	GC	91	PASS	AN=2;DP=65	GT	0/1
chr9	133285950	133285950	A	G	intronic	HMCN2	.	.	.	.	.	.	.	0.12716	.	.	.	2669.68768	9.71594	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	66	39	chr9	133285950	chr9:133285950	A	G	66	PASS	AN=2;DP=39	GT	0/1
chr9	139734633	139734635	AGA	-	exonic	RABL6	.	nonframeshift deletion	RABL6:NM_001173988:exon14:c.1961_1963del:p.K661del,RABL6:NM_024718:exon14:c.1958_1960del:p.K660del	0.970513088	0.029485197	1.72E-06	.	0.10622	0.11255	-0.282886048	33.53385232	162.54419	2.78361	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	35	chr9	139734632	chr9:139734632	GAGA	G	47	PASS	AN=2;DP=35	GT	0/1
chr9	140686493	140686493	T	-	intronic	EHMT1	.	.	.	0.999999904	9.60E-08	3.49E-19	DISEASE: Kleefstra syndrome (KLESTS) [MIM:610253]: A syndrome characterized by severe mental retardation, hypotonia, brachy(micro)cephaly, and facial dysmorphisms. Additionally, congenital heart defects, urogenital defects, epilepsy and behavioral problems are frequently observed. {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}. Note=The disease is caused by mutations affecting the gene represented in this entry (PubMed:16826528). The syndrome can be either caused by intragenic EHMT1 mutations leading to haploinsufficiency of the EHMT1 gene or by a submicroscopic 9q34.3 deletion. Although it is not known if and to what extent other genes in the 9q34.3 region contribute to the syndrome observed in deletion cases, EHMT1 seems to be the major determinant of the core disease phenotype (PubMed:19264732). {ECO:0000269|PubMed:16826528, ECO:0000269|PubMed:19264732}.; 	0.19698	0.1459	-1.582005788	3.13163482	397.32742	4.1876	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	76	40	chr9	140686492	chr9:140686492	CT	C	76	PASS	AN=2;DP=40	GT	0/1
chr10	858611	858611	A	-	UTR3	LARP4B	NM_015155:c.*255delT;NM_001351277:c.*255delT	.	.	0.999885804	0.000114196	1.08E-11	.	0.58444	0.10818	-1.063626766	7.484076433	58.52951	1.54984	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	42	chr10	858610	chr10:858610	GA	G	57	PASS	AN=2;DP=42	GT	0/1
chr10	26534837	26534837	-	T	intronic	GAD2	.	.	.	0.898626708	0.101371704	1.59E-06	.	0.46051	0.86241	-0.111973265	45.35857514	169.77404	2.8426	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	43	chr10	26534837	chr10:26534837	A	AT	42	PASS	AN=2;DP=43	GT	0/1
chr10	48221451	48221451	A	-	intronic	AGAP9	.	.	.	.	.	.	.	0.08138	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	68	97	chr10	48221450	chr10:48221450	TA	T	68	PASS	AN=2;DP=97	GT	0/1
chr10	72620134	72620134	-	T	intronic	SGPL1	.	.	.	0.122514048	0.877267858	0.000218094	.	0.16544	0.43246	-0.290161348	33.33923095	406.33204	4.22621	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	24	chr10	72620134	chr10:72620134	C	CT	53	PASS	AN=2;DP=24	GT	0/1
chr10	81272659	81272659	A	G	exonic	EIF5AL1	.	nonsynonymous SNV	EIF5AL1:NM_001099692:exon1:c.A254G:p.K85R	.	.	.	.	.	0.29774	.	.	18.72537	0.64596	0.091	0.318	T	1.0	0.899	D	0.997	0.850	D	.	.	.	0.950	0.377	D	1.96	0.533	M	0.91	0.449	T	-1.61	0.387	N	0.067	0.054	-0.816	0.542	T	0.190	0.542	T	0.007	0.193	T	2.177	0.323	17.36	0.994	0.641	0.423	0.266	N	c	0.228	0.064	0.091	0.161	0.706	0.609	0	1.02	0.190	3.229	0.507	-1.553	0.009	1.000	0.715	0.289	0.235	5.989	0.186	Nucleic acid-binding, OB-fold|Ribosomal protein L2 domain 2|Translation elongation factor, IF5A C-terminal|Translation protein SH3-like domain	.	.	0.5	57	18	chr10	81272659	chr10:81272659	A	G	57	PASS	AN=2;DP=18	GT	0/1
chr10	100242389	100242389	G	A	intronic	HPSE2	.	.	.	1.85E-06	0.875616336	0.124381812	DISEASE: Urofacial syndrome 1 (UFS1) [MIM:236730]: A rare autosomal recessive disorder characterized by facial grimacing when attempting to smile and failure of the urinary bladder to void completely despite a lack of anatomical bladder outflow obstruction or overt neurological damage. Affected individuals often have reflux of infected urine from the bladder to the upper renal tract, with a risk of kidney damage and renal failure. {ECO:0000269|PubMed:20560209, ECO:0000269|PubMed:20560210}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.29661	0.18462	0.088260113	60.56853031	215.03157	3.16398	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	63	chr10	100242389	chr10:100242389	G	A	59	PASS	AN=2;DP=63	GT	0/1
chr10	101455640	101455640	A	G	UTR3	COX15	NM_001320974:c.*593T>C	.	.	2.16E-09	0.245340645	0.754659352	DISEASE: Leigh syndrome (LS) [MIM:256000]: An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia. {ECO:0000269|PubMed:15235026, ECO:0000269|PubMed:15863660}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.40736	0.14741	-0.246069119	36.06982779	123.8909	2.42262	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	71	14	chr10	101455640	chr10:101455640	A	G	71	PASS	AN=2;DP=14	GT	0/1
chr10	118615126	118615126	T	C	intronic	ENO4	.	.	.	.	.	.	.	.	.	.	.	139.77329	2.5778	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	38	chr10	118615126	chr10:118615126	T	C	.	PASS	AN=0;DP=38	GT	0/1
chr11	18427177	18427177	G	C	intronic	LDHA	.	.	.	0.05865759	0.923941779	0.01740063	DISEASE: Glycogen storage disease 11 (GSD11) [MIM:612933]: A metabolic disorder that results in exertional myoglobinuria, pain, cramps and easy fatigue. {ECO:0000269|PubMed:2334430}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.43011	0.85387	-0.404032746	26.53338051	41.17522	1.20476	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	49	chr11	18427177	chr11:18427177	G	C	60	PASS	AN=2;DP=49	GT	0/1
chr11	35747672	35747672	A	G	exonic	TRIM44	.	synonymous SNV	TRIM44:NM_017583:exon3:c.A948G:p.Q316Q	0.163653747	0.82154148	0.014804773	.	0.5824	0.14627	-0.293801652	32.93819297	23.99448	0.78977	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	73	59	chr11	35747672	chr11:35747672	A	G	73	PASS	AN=2;DP=59	GT	0/1
chr11	45931715	45931715	C	T	exonic	PEX16	.	synonymous SNV	PEX16:NM_057174:exon11:c.G966A:p.A322A	0.001746608	0.972862497	0.025390896	DISEASE: Peroxisome biogenesis disorder complementation group 9 (PBD-CG9) [MIM:614876]: A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS). {ECO:0000269|PubMed:9837814}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Peroxisome biogenesis disorder 8A (PBD8A) [MIM:614876]: A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and clinically characterized by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life. {ECO:0000269|PubMed:9837814}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Peroxisome biogenesis disorder 8B (PBD8B) [MIM:614877]: A relatively mild peroxisome biogenesis disorder. Affected individuals manifest lower limb spasticity and ataxia resulting in wheelchair dependence. Other features include optic atrophy, cataracts, dysarthria, dysphagia, constipation, and a peripheral demyelinating motor and sensory neuropathy. Cognition is relatively preserved. Biochemical abnormalities are mild and include increased very-long-chain fatty acids (VLCFA), increased bile acid intermediates, and increased branched chain fatty acids. Phytanic acid alpha-oxidation, pristanic acid beta-oxidation, and red cell plasmalogen are normal. {ECO:0000269|PubMed:20647552}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.07692	0.19429	0.262810045	70.43524416	256.14052	3.44234	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	112	231	chr11	45931715	chr11:45931715	C	T	112	PASS	AN=2;DP=231	GT	0/1
chr11	64693059	64693059	-	G	UTR5	PPP2R5B	NM_006244:c.-148_-147insG	.	.	0.932458812	0.06752751	1.37E-05	.	0.16145	0.10681	-0.538132194	20.26421326	15.72909	0.56074	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	74	chr11	64693059	chr11:64693059	T	TG	58	PASS	AN=2;DP=74	GT	0/1
chr11	66512290	66512290	-	GGCGGC	exonic	C11orf80	.	nonframeshift insertion	C11orf80:NM_024650:exon1:c.77_78insGGCGGC:p.A34_G35insAA	0.008462596	0.978338462	0.013198942	.	0.03682	.	0.106667882	61.73036093	116.69248	2.34991	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	98	31	chr11	66512290	chr11:66512290	G	GGGCGGC	98	PASS	AN=2;DP=31	GT	0/1
chr11	75277375	75277375	A	G	UTR5	SERPINH1	NM_001207014:c.-20A>G;NM_001235:c.-20A>G	.	.	0.16655085	0.819116317	0.014332833	DISEASE: Osteogenesis imperfecta 10 (OI10) [MIM:613848]: A form of osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Disease severity ranges from very mild forms without fractures to intrauterine fractures and perinatal lethality. Extraskeletal manifestations, which affect a variable number of patients, are dentinogenesis imperfecta, hearing loss, and blue sclerae. OI10 is an autosomal recessive form characterized by multiple bone deformities and fractures, generalized osteopenia, dentinogenesis imperfecta, and blue sclerae. {ECO:0000269|PubMed:20188343}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.83973	0.39597	-0.602450568	17.91106393	54.13484	1.46719	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	100	175	chr11	75277375	chr11:75277375	A	G	100	PASS	AN=2;DP=175	GT	0/1
chr11	100864088	100864088	T	A	UTR3	TMEM133	NM_032021:c.*659T>A	.	.	0.025317131	0.558322413	0.416360457	.	0.06337	.	0.080983847	59.76055674	196.60872	3.03256	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	45	chr11	100864088	chr11:100864088	T	A	.	PASS	AN=0;DP=45	GT	0/1
chr11	119032963	119032963	G	A	UTR3	ABCG4	NM_022169:c.*1147G>A;NM_001348192:c.*1147G>A;NM_001348191:c.*1147G>A;NM_001142505:c.*1147G>A	.	.	0.000455417	0.992033195	0.007511388	.	0.18664	0.15734	-0.067881249	48.69072895	196.06202	3.02988	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	89	110	chr11	119032963	chr11:119032963	G	A	89	PASS	AN=2;DP=110	GT	0/1
chr12	4411082	4411082	-	T	UTR3	CCND2	NM_001759:c.*1907_*1908insT	.	.	0.949000818	0.050836062	0.000163119	DISEASE: Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 (MPPH3) [MIM:615938]: A syndrome characterized by megalencephaly, ventriculomegaly that may lead to hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome. {ECO:0000269|PubMed:24705253}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.93215	0.74954	-0.185391282	39.67916962	14.77663	0.53228	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	44	chr12	4411082	chr12:4411082	G	GT	42	PASS	AN=2;DP=44	GT	0/1
chr12	11461745	11461745	G	C	exonic	PRB4	.	nonsynonymous SNV	PRB4:NM_001261399:exon3:c.C172G:p.Q58E,PRB4:NM_002723:exon3:c.C172G:p.Q58E	8.85E-08	0.165369218	0.834630694	.	.	.	1.352234299	94.36777542	885.28057	5.79602	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	N	.	.	.	3.57	0.047	T	-0.53	0.170	N	0.055	0.097	-0.910	0.469	T	0.007	0.026	T	.	.	.	-3.199	0.001	0.001	0.119	0.002	0.002	0.013	N	c	-2.314	-2.369	0.000	0.042	0.554	0.246	0	-1.49	0.082	-2.301	0.012	-4.823	0.000	0.000	0.063	0.000	0.016	8.663	0.331	.	.	.	0.5	91	81	chr12	11461745	chr12:11461745	G	C	91	PASS	AN=2;DP=81	GT	0/1
chr12	11506830	11506830	T	C	exonic	PRB1	.	synonymous SNV	PRB1:NM_199353:exon3:c.A207G:p.Q69Q,PRB1:NM_199354:exon3:c.A207G:p.Q69Q	2.09E-05	0.477852486	0.522126593	.	.	.	0.305084559	72.22811984	318.00442	3.78677	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	80	155	chr12	11506830	chr12:11506830	T	C	80	PASS	AN=2;DP=155	GT	0/1
chr12	12356138	12356138	G	A	exonic	LRP6	.	nonsynonymous SNV	LRP6:NM_002336:exon3:c.C646T:p.R216W	0.99997833	2.17E-05	5.31E-19	DISEASE: Coronary artery disease, autosomal dominant, 2 (ADCAD2) [MIM:610947]: A common heart disease characterized by reduced or absent blood flow in one or more of the arteries that encircle and supply the heart. Its most important complication is acute myocardial infarction. {ECO:0000269|PubMed:17332414}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.47246	0.47221	-1.699477247	2.565463553	589.91488	4.92398	0.0	0.912	D	1.0	0.899	D	0.997	0.971	D	0.000	0.559	D	1	0.810	D	3.89	0.961	H	-4.48	0.976	D	-6.48	0.958	D	0.354	0.951	1.085	0.991	D	0.964	0.988	D	0.423	0.939	D	6.650	0.912	32	0.999	0.979	0.921	0.546	D	c	0.657	0.530	0.893	0.259	0.732	0.924	0	3.63	0.406	2.155	0.417	1.048	0.713	1.000	0.715	0.999	0.750	14.560	0.676	Six-bladed beta-propeller, TolB-like	.	.	0.5	41	35	chr12	12356138	chr12:12356138	G	A	41	PASS	AN=2;DP=35	GT	0/1
chr12	21639499	21639499	G	T	exonic	RECQL	.	nonsynonymous SNV	RECQL:NM_002907:exon5:c.C415A:p.P139T,RECQL:NM_032941:exon6:c.C415A:p.P139T	7.14E-13	0.063180525	0.936819475	.	0.96604	0.29029	-0.973616687	8.8995046	602.74519	4.96976	0.0	0.912	D	1.0	0.899	D	1.0	0.971	D	0.000	0.843	D	1	0.810	D	4.72	0.995	H	0.53	0.551	T	-7.74	0.965	D	0.962	0.961	0.629	0.923	D	0.600	0.858	D	0.061	0.682	D	5.884	0.807	27.4	0.998	0.860	0.991	0.913	D	c	1.183	1.068	1.000	0.747	0.732	0.924	0	5.63	0.861	9.044	0.932	1.029	0.652	1.000	0.715	0.993	0.574	19.710	0.961	DEAD/DEAH box helicase domain|Helicase superfamily 1/2, ATP-binding domain|P-loop containing nucleoside triphosphate hydrolase	.	.	0.5	.	46	chr12	21639499	chr12:21639499	G	T	.	PASS	AN=0;DP=46	GT	0/1
chr12	27648786	27648786	A	G	exonic	SMCO2	.	synonymous SNV	SMCO2:NM_001145010:exon8:c.A831G:p.A277A	.	.	.	.	.	.	0.881944684	89.02453409	398.02888	4.19168	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	97	26	chr12	27648786	chr12:27648786	A	G	97	PASS	AN=2;DP=26	GT	0/1
chr12	29486506	29486507	AG	-	intronic	FAR2	.	.	.	0.922173888	0.077806487	1.96E-05	.	0.11607	0.13485	-0.844966979	11.1759849	59.26666	1.56096	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	16.87	39	chr12	29486505	chr12:29486505	CAG	C,CTAG	16.87	PASS	AN=0;DP=39	GT	0/1
chr12	29486505	29486505	-	T	intronic	FAR2	.	.	.	0.922173888	0.077806487	1.96E-05	.	0.11607	0.13485	-0.844966979	11.1759849	59.26666	1.56096	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	16.87	39	chr12	29486505	chr12:29486505	CAG	C,CTAG	16.87	PASS	AN=0;DP=39	GT	0/1
chr12	29812859	29812859	A	T	intronic	TMTC1	.	.	.	3.06E-07	0.996221773	0.003777921	.	0.33022	0.13818	-0.418800956	25.79028073	1433.09079	7.06654	0.998	0.019	T	0.998	0.715	D	0.991	0.782	D	.	.	.	0.992	0.810	D	.	.	.	0.91	0.449	T	-0.81	0.223	N	0.309	0.465	-0.613	0.643	T	0.242	0.611	T	0.132	0.815	D	3.177	0.441	22.7	0.992	0.536	0.957	0.657	D	c	0.642	0.647	1.000	0.480	0.706	0.609	0	5.4	0.779	7.390	0.789	1.088	0.866	1.000	0.715	0.998	0.697	11.814	0.513	Domain of unknown function DUF1736	.	.	0.5	.	25	chr12	29812859	chr12:29812859	A	T	.	PASS	AN=0;DP=25	GT	0/1
chr12	31289663	31289663	A	-	intergenic	DDX11;FAM60A	dist=31938;dist=143857	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	22	chr12	31289662	chr12:31289662	TA	T	58	PASS	AN=2;DP=22	GT	0/1
chr12	53073971	53073973	ACC	-	exonic	KRT1	.	nonframeshift deletion	KRT1:NM_006121:exon1:c.160_162del:p.G54del	0.973618209	0.026380488	1.30E-06	DISEASE: Epidermolytic hyperkeratosis (EHK) [MIM:113800]: An autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop. {ECO:0000269|PubMed:10232403, ECO:0000269|PubMed:10688370, ECO:0000269|PubMed:10844506, ECO:0000269|PubMed:11531804, ECO:0000269|PubMed:12406348, ECO:0000269|PubMed:1380725, ECO:0000269|PubMed:1381288, ECO:0000269|PubMed:21271994, ECO:0000269|PubMed:7507151, ECO:0000269|PubMed:7507152, ECO:0000269|PubMed:7512983, ECO:0000269|PubMed:9856846}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis hystrix, Curth-Macklin type (IHCM) [MIM:146590]: A genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks. {ECO:0000269|PubMed:11286616}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, non-epidermolytic (NEPPK) [MIM:600962]: A dermatological disorder characterized by well- demarcated hyperkeratosis is present over the palms and soles. A red band is frequently present at the periphery of the keratosis. It is usually non-transgredient, with a sharp demarcation of the lesions at the wrists. {ECO:0000269|PubMed:11286630, ECO:0000269|PubMed:7528239}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ichthyosis annular epidermolytic (AEI) [MIM:607602]: A skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months. {ECO:0000269|PubMed:10053007, ECO:0000269|PubMed:10597140}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Keratoderma, palmoplantar, striate 3 (SPPK3) [MIM:607654]: A dermatological disorder characterized by thickening of the stratum corneum and epidermal layers on palms and soles. There is no involvement of non-palmoplantar skin, and both hair and nails are normal. {ECO:0000269|PubMed:11982762}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.79851	0.61014	0.709197509	85.68058504	4311.14232	13.06797	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	51	44	chr12	53073970	chr12:53073970	TACC	T	51	PASS	AN=2;DP=44	GT	0/1
chr12	57638386	57638386	T	A	exonic	STAC3	.	nonsynonymous SNV	STAC3:NM_001286257:exon6:c.A182T:p.Q61L,STAC3:NM_001286256:exon8:c.A623T:p.Q208L,STAC3:NM_145064:exon9:c.A740T:p.Q247L	0.004878302	0.989072823	0.006048875	DISEASE: Native American myopathy (NAM) [MIM:255995]: A disease characterized by congenital weakness and arthrogryposis, cleft palate, ptosis, short stature, kyphoscoliosis, talipes deformities, and susceptibility to malignant hyperthermia provoked by anesthesia. {ECO:0000269|PubMed:23736855}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.16182	0.10482	-0.137658575	43.57159707	50.70761	1.40292	0.26	0.165	T	0.01	0.144	B	0.004	0.093	B	0.104	0.197	N	0.750	0.306	N	1.15	0.294	L	1.62	0.282	T	-0.09	0.090	N	0.42	0.477	-1.018	0.244	T	0.021	0.087	T	0.008	0.226	T	2.404	0.350	18.85	0.973	0.329	0.810	0.402	D	c	-0.565	-0.295	1.000	0.500	0.706	0.609	0	3.87	0.437	0.181	0.166	0.964	0.580	0.991	0.370	1.000	0.888	6.628	0.219	SH3 domain	.	.	0.5	74	62	chr12	57638386	chr12:57638386	T	A	74	PASS	AN=2;DP=62	GT	0/1
chr12	72094581	72094581	T	C	intronic	TMEM19	.	.	.	0.001380694	0.866114693	0.132504613	.	0.0797	0.1104	0.350995466	74.37485256	257.67543	3.45315	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	100	87	chr12	72094581	chr12:72094581	T	C	100	PASS	AN=2;DP=87	GT	0/1
chr12	72665887	72665887	T	A	ncRNA_exonic	TRHDE-AS1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	127	317	chr12	72665887	chr12:72665887	T	A	127	PASS	AN=2;DP=317	GT	0/1
chr12	125603260	125603260	C	-	exonic	AACS	.	frameshift deletion	AACS:NM_001319839:exon10:c.1070delC:p.L359Wfs*14,AACS:NM_001319840:exon10:c.1070delC:p.L359Wfs*14,AACS:NM_023928:exon10:c.1070delC:p.L359Wfs*14	4.25E-12	0.171790101	0.828209899	.	0.18243	0.23898	-1.170241634	6.039160179	163.63033	2.79374	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	48	76	chr12	125603259	chr12:125603259	TC	T	48	PASS	AN=2;DP=76	GT	0/1
chr13	32907536	32907536	T	-	intronic	BRCA2	.	.	.	2.21E-15	0.999975298	2.47E-05	DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. {ECO:0000269|PubMed:10399947, ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:11139248, ECO:0000269|PubMed:11241844, ECO:0000269|PubMed:11948477, ECO:0000269|PubMed:12145750, ECO:0000269|PubMed:12373604, ECO:0000269|PubMed:12442274, ECO:0000269|PubMed:12442275, ECO:0000269|PubMed:12938098, ECO:0000269|PubMed:14722926, ECO:0000269|PubMed:15026808, ECO:0000269|PubMed:15172753, ECO:0000269|PubMed:15365993, ECO:0000269|PubMed:8640237, ECO:0000269|PubMed:9150152, ECO:0000269|PubMed:9609997, ECO:0000269|PubMed:9654203, ECO:0000269|PubMed:9971877}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Pancreatic cancer 2 (PNCA2) [MIM:613347]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. {ECO:0000269|PubMed:9140390}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Breast-ovarian cancer, familial, 2 (BROVCA2) [MIM:612555]: A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Fanconi anemia complementation group D1 (FANCD1) [MIM:605724]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:12065746, ECO:0000269|PubMed:14670928, ECO:0000269|PubMed:16825431}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Glioma 3 (GLM3) [MIM:613029]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15689453}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.97144	0.70346	3.731883424	99.58716678	775.59808	5.51436	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	75	20	chr13	32907535	chr13:32907535	CT	C	75	PASS	AN=2;DP=20	GT	0/1
chr14	21702046	21702046	-	A	intronic	HNRNPC	.	.	.	0.985848437	0.014144716	6.85E-06	.	0.16171	0.28104	-0.075159878	47.78839349	6.88559	0.25634	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	11	chr14	21702046	chr14:21702046	C	CA	41	PASS	AN=2;DP=11	GT	0/1
chr14	32561340	32561340	G	A	exonic	ARHGAP5	.	nonsynonymous SNV	ARHGAP5:NM_001030055:exon2:c.G1465A:p.E489K,ARHGAP5:NM_001173:exon2:c.G1465A:p.E489K	0.987053698	0.012946293	9.23E-09	.	0.23723	0.16401	-0.545632343	20.02241095	177.4302	2.89547	0.043	0.413	D	0.734	0.422	P	0.562	0.519	P	0.000	0.843	D	1	0.810	D	0	0.065	N	1.47	0.320	T	-1.43	0.352	N	0.567	0.601	-1.060	0.117	T	0.106	0.388	T	.	.	.	4.656	0.624	24.5	0.998	0.901	0.993	0.948	D	c	0.617	0.730	1.0	0.983	0.707	0.730	0	6.02	0.975	10.003	0.997	1.048	0.713	1.000	0.715	1.000	0.888	20.547	0.993	FF domain	.	.	0.5	52	29	chr14	32561340	chr14:32561340	G	A	52	PASS	AN=2;DP=29	GT	0/1
chr14	33408505	33408505	A	-	UTR5	NPAS3	NM_001164749:c.-18del-;NM_001165893:c.-18del-;NM_022123:c.-18del-;NM_173159:c.-18del-	.	.	0.98054867	0.019451206	1.24E-07	.	0.30103	0.1462	-1.350267166	4.600141543	902.6267	5.84777	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	88	chr14	33408504	chr14:33408504	GA	G	69	PASS	AN=2;DP=88	GT	0/1
chr14	36096377	36096377	G	A	exonic	RALGAPA1	.	nonsynonymous SNV	RALGAPA1:NM_001330075:exon33:c.C6635T:p.P2212L,RALGAPA1:NM_001346243:exon33:c.C5258T:p.P1753L,RALGAPA1:NM_001346246:exon33:c.C5258T:p.P1753L,RALGAPA1:NM_001346248:exon33:c.C6635T:p.P2212L,RALGAPA1:NM_014990:exon33:c.C5258T:p.P1753L,RALGAPA1:NM_194301:exon33:c.C5258T:p.P1753L,RALGAPA1:NM_001283043:exon34:c.C5297T:p.P1766L,RALGAPA1:NM_001283044:exon34:c.C5399T:p.P1800L,RALGAPA1:NM_001346245:exon34:c.C5399T:p.P1800L,RALGAPA1:NM_001346247:exon34:c.C5399T:p.P1800L,RALGAPA1:NM_001346249:exon34:c.C6776T:p.P2259L	0.999999978	2.19E-08	3.25E-24	.	0.75239	0.12918	-1.210720546	5.708893607	2267.65022	8.8021	0.001	0.784	D	1.0	0.899	D	0.999	0.916	D	0.000	0.629	N	1.000	0.810	D	2.07	0.570	M	-3.11	0.927	D	-7.27	0.967	D	0.231	0.418	-0.384	0.726	T	0.361	0.723	T	0.331	0.918	D	4.690	0.629	24.6	0.996	0.728	0.943	0.605	D	c	0.113	0.145	0.818	0.244	0.615	0.372	0	3.58	0.400	8.095	0.893	-0.234	0.093	1.000	0.715	0.988	0.529	12.161	0.532	Rap GTPase activating protein domain	.	.	0.5	.	40	chr14	36096377	chr14:36096377	G	A	.	PASS	AN=0;DP=40	GT	0/1
chr14	45716019	45716019	T	-	exonic	MIS18BP1	.	frameshift deletion	MIS18BP1:NM_018353:exon2:c.471delA:p.K157Nfs*23	2.30E-05	0.999045195	0.000931804	.	0.25957	0.06969	1.743518989	96.6383581	1469.92348	7.14407	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	31	chr14	45716018	chr14:45716018	AT	A	42	PASS	AN=2;DP=31	GT	0/1
chr14	74409329	74409329	G	A	exonic	FAM161B	.	nonsynonymous SNV	FAM161B:NM_152445:exon4:c.C1204T:p.R402W	9.86E-11	0.27905519	0.72094481	.	0.09509	0.08229	0.536463361	81.06864827	3600.98595	11.61635	0.007	0.599	D	0.999	0.764	D	0.877	0.604	P	0.872	0.088	N	1	0.090	N	2.72	0.798	M	1.86	0.243	T	-2.32	0.514	N	0.083	0.334	-0.982	0.346	T	0.106	0.387	T	0.019	0.413	T	1.981	0.299	16.09	0.992	0.560	0.174	0.196	N	c	-0.640	-0.899	1.000	0.500	0.651	0.465	0	-3.09	0.050	0.953	0.286	-1.318	0.013	0.026	0.200	0.000	0.016	5.619	0.166	.	.	.	0.5	83	162	chr14	74409329	chr14:74409329	G	A	83	PASS	AN=2;DP=162	GT	0/1
chr14	74534275	74534275	A	-	intronic	ALDH6A1	.	.	.	1.62E-05	0.992502487	0.00748129	DISEASE: Methylmalonate semialdehyde dehydrogenase deficiency (MMSDHD) [MIM:614105]: A metabolic disorder characterized by elevated beta-alanine, 3-hydroxypropionic acid, and both isomers of 3-amino and 3-hydroxyisobutyric acids in urine organic acids. {ECO:0000269|PubMed:10947204}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.20099	0.21694	-0.402212257	26.7338995	42.69019	1.23859	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	85	chr14	74534274	chr14:74534274	TA	T	52	PASS	AN=2;DP=85	GT	0/1
chr14	91467522	91467522	A	-	intronic	RPS6KA5	.	.	.	0.999801807	0.000198193	4.15E-11	.	0.66327	0.31031	-0.178111357	40.44585987	117.20806	2.35411	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	59	73	chr14	91467521	chr14:91467521	GA	G	59	PASS	AN=2;DP=73	GT	0/1
chr14	102302490	102302490	-	T	intronic	PPP2R5C	.	.	.	0.997672663	0.00232732	1.68E-08	.	0.16008	0.12741	0.018483465	55.44939844	1821.40468	7.87398	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	79	75	chr14	102302490	chr14:102302490	G	GT	79	PASS	AN=2;DP=75	GT	0/1
chr14	106993734	106993734	C	G	intergenic	LINC00221;MIR7641-2	dist=42205;dist=98982	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	30	chr14	106993734	chr14:106993734	C	G	69	PASS	AN=2;DP=30	GT	0/1
chr15	44941137	44941137	C	T	exonic	SPG11	.	nonsynonymous SNV	SPG11:NM_001160227:exon7:c.G1529A:p.S510N,SPG11:NM_025137:exon7:c.G1529A:p.S510N	2.91E-22	0.995686251	0.004313749	.	0.48298	0.1128	-0.481610219	22.78839349	5573.81365	15.43136	0.167	0.332	T	1.0	0.899	D	0.999	0.916	D	0.000	0.843	N	0.999	0.467	D	2.74	0.803	M	-1.42	0.807	T	-1.1	0.314	N	0.052	0.094	0.170	0.854	D	0.608	0.861	D	0.038	0.580	D	5.898	0.809	27.5	0.993	0.596	0.900	0.506	D	c	0.545	0.535	1.000	0.424	0.707	0.730	0	4.93	0.643	3.608	0.536	0.935	0.490	1.000	0.715	1.000	0.888	14.360	0.662	.	.	.	0.5	59	37	chr15	44941137	chr15:44941137	C	T	59	PASS	AN=2;DP=37	GT	0/1
chr15	62534764	62534764	A	-	ncRNA_exonic	GOLGA2P11	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	29.9	59	chr15	62534763	chr15:62534763	TA	T	29.9	PASS	AN=0;DP=59	GT	0/1
chr15	75981972	75981972	A	G	exonic	CSPG4	.	synonymous SNV	CSPG4:NM_001897:exon3:c.T1434C:p.H478H	8.90E-05	0.999905547	5.48E-06	.	0.14288	0.14191	0.347031518	73.79098844	3644.03559	11.72399	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	104	chr15	75981972	chr15:75981972	A	G	.	PASS	AN=0;DP=104	GT	0/1
chr15	75981976	75981976	C	T	exonic	CSPG4	.	nonsynonymous SNV	CSPG4:NM_001897:exon3:c.G1430A:p.R477H	8.90E-05	0.999905547	5.48E-06	.	0.14288	0.14191	0.347031518	73.79098844	3644.03559	11.72399	0.544	0.067	T	0.513	0.355	P	0.079	0.272	B	0.000	0.443	D	0.953	0.264	N	2.595	0.761	M	2.14	0.194	T	-1.73	0.410	N	0.372	0.433	-1.046	0.155	T	0.043	0.183	T	0.012	0.305	T	1.800	0.277	14.99	0.985	0.415	0.249	0.223	N	c	-0.353	-0.402	0.998	0.357	0.554	0.283	0	4.19	0.485	0.882	0.276	0.785	0.317	0.003	0.159	0.003	0.074	9.359	0.372	.	.	.	0.5	.	107	chr15	75981976	chr15:75981976	C	T	.	PASS	AN=0;DP=107	GT	0/1
chr15	78397503	78397503	-	T	UTR3	CIB2	NM_001301224:c.*149_*150insA;NM_001271889:c.*149_*150insA;NM_001271888:c.*149_*150insA;NM_006383:c.*149_*150insA	.	.	0.000468493	0.667683033	0.331848474	DISEASE: Usher syndrome 1J (USH1J) [MIM:614869]: USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness. {ECO:0000269|PubMed:23023331}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.40943	0.13588	-0.293801652	32.93819297	57.97419	1.53939	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	36	chr15	78397503	chr15:78397503	G	GT	54	PASS	AN=2;DP=36	GT	0/1
chr15	89659704	89659704	C	T	exonic	ABHD2	.	nonsynonymous SNV	ABHD2:NM_152924:exon3:c.C146T:p.S49L,ABHD2:NM_007011:exon7:c.C146T:p.S49L	0.84946372	0.150426271	0.000110009	.	0.19174	0.12265	-0.025608647	51.91672564	42.87383	1.24066	0.063	0.614	T	0.377	0.325	B	0.079	0.272	B	0.000	0.629	D	1.000	0.588	D	1.525	0.387	L	2.36	0.161	T	-2.73	0.757	D	0.404	0.481	-1.130	0.018	T	0.042	0.181	T	0.010	0.255	T	4.455	0.596	24.2	0.998	0.927	0.991	0.913	D	c	0.320	0.490	1.0	0.983	0.707	0.730	0	5.91	0.952	7.905	0.864	0.935	0.490	1.000	0.715	0.995	0.604	20.299	0.986	.	.	.	0.5	65	63	chr15	89659704	chr15:89659704	C	T	65	PASS	AN=2;DP=63	GT	0/1
chr15	90808018	90808018	T	C	upstream	NGRN	dist=877	.	.	0.022406215	0.910697225	0.06689656	.	0.03947	.	-0.047654689	50.22410946	226.47856	3.25183	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	47	65	chr15	90808018	chr15:90808018	T	C	47	PASS	AN=2;DP=65	GT	0/1
chr16	1382898	1382898	-	A	upstream	BAIAP3	dist=708	.	.	2.21E-19	0.088488031	0.911511969	.	0.29593	0.09988	-2.150176731	1.468506723	719.07294	5.32413	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	133	chr16	1382898	chr16:1382898	G	GA	41	PASS	AN=2;DP=133	GT	0/1
chr16	5037498	5037498	-	G	intronic	SEC14L5	.	.	.	6.57E-10	0.408296631	0.591703368	.	0.15183	.	-1.703090605	2.535975466	83.7768	1.94866	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	99	52	chr16	5037498	chr16:5037498	T	TG	99	PASS	AN=2;DP=52	GT	0/1
chr16	18872151	18872151	-	A	intronic	SMG1	.	.	.	1	4.40E-14	1.05E-36	.	.	.	-2.975494782	0.542580797	910.18577	5.86659	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	66	106	chr16	18872151	chr16:18872151	T	TA	66	PASS	AN=2;DP=106	GT	0/1
chr16	19127777	19127777	-	A	UTR3	ITPRIPL2	NM_001034841:c.*386_*387insA	.	.	0.018503394	0.896702885	0.084793722	.	.	.	0.551232944	81.48148148	484.31785	4.52979	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	14	chr16	19127777	chr16:19127777	T	TA	40	PASS	AN=2;DP=14	GT	0/1
chr16	28883182	28883182	C	T	exonic	SH2B1	.	nonsynonymous SNV	SH2B1:NM_001308294:exon5:c.C383T:p.S128L,SH2B1:NM_015503:exon5:c.C1391T:p.S464L,SH2B1:NM_001145795:exon6:c.C1391T:p.S464L,SH2B1:NM_001145796:exon6:c.C1391T:p.S464L,SH2B1:NM_001145797:exon6:c.C1391T:p.S464L,SH2B1:NM_001145812:exon6:c.C1391T:p.S464L,SH2B1:NM_001308293:exon8:c.C1391T:p.S464L	0.95682971	0.043165859	4.43E-06	.	0.50303	0.23508	-0.244249595	36.17008728	1577.15232	7.34901	0.012	0.546	D	0.99	0.764	D	0.53	0.611	P	0.027	0.259	N	0.998	0.446	D	0.695	0.181	N	0.8	0.491	T	-0.99	0.262	N	0.796	0.834	-0.858	0.515	T	0.157	0.490	T	0.023	0.464	T	6.125	0.844	28.3	0.999	0.974	0.986	0.846	D	c	0.420	0.484	1.000	0.747	0.707	0.730	0	5.14	0.699	2.597	0.456	0.892	0.403	0.989	0.365	0.998	0.697	17.383	0.872	.	.	.	0.5	60	207	chr16	28883182	chr16:28883182	C	T	60	PASS	AN=2;DP=207	GT	0/1
chr16	30016652	30016652	-	C	exonic	INO80E	.	frameshift insertion	INO80E:NM_001304562:exon6:c.508dupC:p.T173Hfs*15,INO80E:NM_173618:exon7:c.625dupC:p.T212Hfs*15	0.017414685	0.891403715	0.0911816	.	0.18786	0.11011	-0.073340031	48.11866006	41.31906	1.20769	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	44	chr16	30016652	chr16:30016652	G	GC	61	PASS	AN=2;DP=44	GT	0/1
chr16	84900431	84900431	T	-	intronic	CRISPLD2	.	.	.	7.38E-06	0.977631394	0.02236123	.	0.77714	0.10639	0.448277766	77.99598962	4030.53322	12.57901	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	44	16	chr16	84900430	chr16:84900430	CT	C	44	PASS	AN=2;DP=16	GT	0/1
chr17	26522835	26522835	T	-	UTR3	NLK	NM_016231:c.*1173delT	.	.	0.998934347	0.001065641	1.24E-08	.	0.96706	0.16306	-0.494039303	22.09247464	16.84134	0.5932	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	29	chr17	26522834	chr17:26522834	AT	A	61	PASS	AN=2;DP=29	GT	0/1
chr17	28011635	28011653	CTACCATTAGTTGAAACCA	-	exonic	SSH2	.	frameshift deletion	SSH2:NM_001282131:exon4:c.347_365del:p.V116Dfs*9,SSH2:NM_001282130:exon5:c.326_344del:p.V109Dfs*9,SSH2:NM_033389:exon5:c.326_344del:p.V109Dfs*9,SSH2:NM_001282129:exon6:c.407_425del:p.V136Dfs*9	0.999753485	0.000246515	5.85E-13	.	0.53245	0.09592	-0.099241008	45.68294409	1818.77446	7.86582	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	41	83	chr17	28011634	chr17:28011634	TCTACCATTAGTTGAAACCA	T	41	PASS	AN=2;DP=83	GT	0/1
chr17	30320860	30320860	-	T	intronic	SUZ12	.	.	.	0.999270636	0.000729363	9.92E-10	DISEASE: Note=A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is frequently found in all cases of endometrial stromal tumors, except in endometrial stromal sarcomas, where it is rarer. {ECO:0000269|PubMed:11371647}.; 	0.90035	.	-0.159704656	41.90846898	37.06069	1.10711	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	54	17	chr17	30320860	chr17:30320860	C	CT	54	PASS	AN=2;DP=17	GT	0/1
chr17	36883483	36883483	-	T	UTR3	MLLT6	NM_005937:c.*1632_*1633insT	.	.	0.998762157	0.001237842	7.29E-10	DISEASE: Note=A chromosomal aberration involving MLLT6 is associated with acute leukemias. Translocation t(11;17)(q23;q21) with KMT2A/MLL1. The result is a rogue activator protein.; 	0.50287	0.15426	-0.020150552	52.25288983	264.58482	3.48969	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	81	47	chr17	36883483	chr17:36883483	G	GT	81	PASS	AN=2;DP=47	GT	0/1
chr17	48653249	48653251	CAC	-	exonic	CACNA1G	.	nonframeshift deletion	CACNA1G:NM_001256324:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256325:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256326:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256327:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256328:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256329:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256330:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256331:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256332:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256333:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256334:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256359:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256360:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_001256361:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_018896:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198376:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198377:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198378:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198379:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198380:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198382:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198383:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198384:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198385:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198386:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198387:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198388:exon8:c.1486_1488del:p.H504del,CACNA1G:NM_198396:exon8:c.1486_1488del:p.H504del	0.999996517	3.48E-06	7.46E-19	.	0.50605	0.17372	-2.374358198	1.114649682	288.88842	3.63697	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	62	59	chr17	48653248	chr17:48653248	GCAC	G	62	PASS	AN=2;DP=59	GT	0/1
chr17	58300951	58300951	-	A	intronic	USP32	.	.	.	0.999999997	2.88E-09	5.68E-25	.	0.99543	0.10507	-2.078019896	1.580561453	184.4083	2.94681	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	40	14	chr17	58300951	chr17:58300951	T	TA	40	PASS	AN=2;DP=14	GT	0/1
chr17	72368450	72368450	C	T	exonic	GPR142	.	nonsynonymous SNV	GPR142:NM_001331076:exon4:c.C836T:p.T279I,GPR142:NM_001331077:exon4:c.C836T:p.T279I,GPR142:NM_181790:exon4:c.C1100T:p.T367I	5.60E-05	0.689421967	0.310522078	.	.	.	-0.214928658	37.7388535	583.16278	4.89646	0.463	0.086	T	0.166	0.295	B	0.038	0.234	B	0.120	0.190	N	0.982	0.250	N	0.14	0.088	N	-0.36	0.688	T	0.17	0.051	N	0.156	0.186	-1.036	0.187	T	0.105	0.384	T	0.027	0.500	D	1.117	0.202	11.31	0.909	0.196	0.315	0.241	N	c	-0.610	-0.497	0.068	0.155	0.497	0.185	0	3.63	0.406	2.018	0.404	0.925	0.434	0.005	0.169	0.980	0.490	6.953	0.236	GPCR, rhodopsin-like, 7TM	.	.	0.5	112	101	chr17	72368450	chr17:72368450	C	T	112	PASS	AN=2;DP=101	GT	0/1
chr17	73262902	73262904	CAG	-	exonic	MIF4GD	.	nonframeshift deletion	MIF4GD:NM_001242501:exon5:c.586_588del:p.L196del,MIF4GD:NM_001242500:exon6:c.688_690del:p.L230del,MIF4GD:NM_001242498:exon7:c.709_711del:p.L237del,MIF4GD:NM_020679:exon7:c.688_690del:p.L230del	3.58E-05	0.592434276	0.407529922	.	0.03324	.	-0.183570861	39.95046001	1028.74548	6.16188	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	79	70	chr17	73262901	chr17:73262901	CCAG	C	79	PASS	AN=2;DP=70	GT	0/1
chr18	8376501	8376501	T	C	exonic	PTPRM	.	nonsynonymous SNV	PTPRM:NM_002845:exon24:c.T3329C:p.I1110T,PTPRM:NM_001105244:exon26:c.T3368C:p.I1123T	0.999958214	4.18E-05	1.30E-17	.	0.20617	0.12992	-2.02851154	1.704411418	316.58577	3.77934	0.306	0.142	T	0.707	0.715	P	0.599	0.875	P	0.000	0.843	D	1	0.810	D	1.31	0.329	L	1.5	0.312	T	-2.04	0.468	N	0.871	0.934	-1.026	0.218	T	0.106	0.388	T	0.024	0.471	T	3.426	0.470	23.0	0.998	0.890	0.978	0.774	D	c	0.475	0.569	1.000	0.747	0.638	0.428	0	5.88	0.945	8.017	0.886	1.011	0.635	1.000	0.715	1.000	0.888	16.290	0.825	PTP type protein phosphatase|Protein-tyrosine phosphatase-like|Tyrosine specific protein phosphatases domain	.	.	0.5	110	72	chr18	8376501	chr18:8376501	T	C	110	PASS	AN=2;DP=72	GT	0/1
chr18	66358515	66358516	AA	-	exonic	TMX3	.	stopgain	TMX3:NM_001350513:exon8:c.572_573del:p.F191fs*0	0.191322508	0.808583205	9.43E-05	.	0.25561	0.11004	0.240763792	69.36777542	113.00046	2.31345	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	17	chr18	66358514	chr18:66358514	TAA	T	60	PASS	AN=2;DP=17	GT	0/1
chr18	72223645	72223645	G	T	exonic	CNDP1	.	nonsynonymous SNV	CNDP1:NM_032649:exon2:c.G97T:p.A33S	1.91E-05	0.97216589	0.027815013	.	0.11983	0.24162	1.247448154	93.43595188	1273.96612	6.72127	0.784	0.032	T	0.0	0.026	B	0.0	0.013	B	0.447	0.125	N	1	0.090	N	-0.11	0.046	N	2.55	0.138	T	0.5	0.030	N	0.094	0.137	-0.973	0.365	T	0.014	0.056	T	0.005	0.119	T	-0.699	0.045	0.072	0.477	0.039	0.089	0.146	N	c	-1.093	-0.995	1.000	0.436	0.516	0.203	0	4.1	0.470	0.407	0.206	1.048	0.713	0.000	0.063	0.001	0.043	10.045	0.412	.	.	.	0.5	83	81	chr18	72223645	chr18:72223645	G	T	83	PASS	AN=2;DP=81	GT	0/1
chr19	1506040	1506040	G	A	exonic	ADAMTSL5	.	synonymous SNV	ADAMTSL5:NM_213604:exon12:c.C1390T:p.L464L	3.22E-10	0.086390501	0.913609499	.	0.15136	0.10435	0.442818085	77.8544468	191.46176	3.00098	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	131	149	chr19	1506040	chr19:1506040	G	A	131	PASS	AN=2;DP=149	GT	0/1
chr19	7116823	7116823	G	A	UTR3	INSR	NM_001079817:c.*244C>T;NM_000208:c.*244C>T	.	.	0.186547844	0.813452149	6.81E-09	DISEASE: Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin resistance syndrome characterized by insulin-resistant diabetes mellitus with pineal hyperplasia and somatic abnormalities. Typical features include coarse, senile-appearing facies, dental and skin abnormalities, abdominal distension, and phallic enlargement. Inheritance is autosomal recessive. {ECO:0000269|PubMed:10443650, ECO:0000269|PubMed:12023989, ECO:0000269|PubMed:17201797, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:8314008}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Leprechaunism (LEPRCH) [MIM:246200]: Represents the most severe form of insulin resistance syndrome, characterized by intrauterine and postnatal growth retardation and death in early infancy. Inheritance is autosomal recessive. {ECO:0000269|PubMed:12538626, ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1607067, ECO:0000269|PubMed:1730625, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2479553, ECO:0000269|PubMed:2834824, ECO:0000269|PubMed:7538143, ECO:0000269|PubMed:7815442, ECO:0000269|PubMed:8188715, ECO:0000269|PubMed:8326490, ECO:0000269|PubMed:8419945, ECO:0000269|PubMed:8636294, ECO:0000269|PubMed:9249867, ECO:0000269|PubMed:9703342}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:1470163, ECO:0000269|PubMed:1607076, ECO:0000269|PubMed:7657032}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Familial hyperinsulinemic hypoglycemia 5 (HHF5) [MIM:609968]: Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels. {ECO:0000269|PubMed:15161766}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Insulin-resistant diabetes mellitus with acanthosis nigricans type A (IRAN type A) [MIM:610549]: Characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor. {ECO:0000269|PubMed:10733238, ECO:0000269|PubMed:11260230, ECO:0000269|PubMed:12107746, ECO:0000269|PubMed:12970295, ECO:0000269|PubMed:1563582, ECO:0000269|PubMed:1963473, ECO:0000269|PubMed:2002058, ECO:0000269|PubMed:2168397, ECO:0000269|PubMed:2365819, ECO:0000269|PubMed:2544998, ECO:0000269|PubMed:3283938, ECO:0000269|PubMed:8243830, ECO:0000269|PubMed:8288049, ECO:0000269|PubMed:8314008, ECO:0000269|PubMed:8388389, ECO:0000269|PubMed:9175790}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.99973	0.94105	-2.140595475	1.492097193	141.47735	2.59553	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	81	chr19	7116823	chr19:7116823	G	A	.	PASS	AN=0;DP=81	GT	0/1
chr19	11591325	11591325	C	-	intronic	ELAVL3	.	.	.	0.822602584	0.176556392	0.000841025	.	0.39015	0.23372	-0.780646273	12.77423921	9.21155	0.33694	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	231	chr19	11591324	chr19:11591324	AC	A	84	PASS	AN=2;DP=231	GT	0/1
chr19	14003635	14003635	C	T	exonic	C19orf57	.	nonsynonymous SNV	C19orf57:NM_001345846:exon4:c.G3A:p.M1I,C19orf57:NM_001345847:exon4:c.G3A:p.M1I,C19orf57:NM_001345843:exon5:c.G774A:p.M258I,C19orf57:NM_001345844:exon5:c.G774A:p.M258I,C19orf57:NM_001345848:exon5:c.G774A:p.M258I,C19orf57:NM_024323:exon5:c.G357A:p.M119I	7.18E-05	0.91292763	0.087000543	.	0.06931	0.07027	2.050415361	97.77070064	3198.91219	10.78072	0.471	0.084	T	0.0	0.026	B	0.001	0.040	B	0.106	0.026	N	1	0.090	N	0.69	0.170	N	1.61	0.284	T	-1.43	0.352	N	0.063	0.048	-1.050	0.143	T	0.037	0.161	T	0.002	0.043	T	-3.350	0.001	0.001	0.339	0.020	0.003	0.016	N	c	-2.509	-2.585	1.000	0.747	0.615	0.372	0	-9.22	0.006	-3.186	0.006	-1.722	0.007	0.000	0.063	0.000	0.016	9.940	0.406	.	.	.	0.5	.	57	chr19	14003635	chr19:14003635	C	T	.	PASS	AN=0;DP=57	GT	0/1
chr19	14749076	14749076	A	G	exonic	ADGRE3	.	nonsynonymous SNV	ADGRE3:NM_001289159:exon8:c.T947C:p.V316A,ADGRE3:NM_001289158:exon10:c.T1169C:p.V390A,ADGRE3:NM_032571:exon11:c.T1325C:p.V442A	.	.	.	.	0.07768	.	1.223576934	93.23543289	.	.	0.002	0.721	D	0.263	0.423	B	0.314	0.586	B	.	.	.	1.000	0.182	N	2.56	0.750	M	0.96	0.429	T	-1.93	0.448	N	0.163	0.196	-0.926	0.447	T	0.194	0.547	T	0.009	0.240	T	1.901	0.289	15.59	0.893	0.181	0.971	0.726	D	c	-0.195	-0.236	0.017	0.129	0.500	0.196	0	3.43	0.382	6.097	0.709	0.093	0.196	1.000	0.715	0.661	0.301	9.507	0.380	GPCR, family 2-like	.	.	0.5	85	108	chr19	14749076	chr19:14749076	A	G	85	PASS	AN=2;DP=108	GT	0/1
chr19	22942325	22942325	G	C	exonic	ZNF99	.	nonsynonymous SNV	ZNF99:NM_001080409:exon4:c.C386G:p.A129G	3.04E-09	0.162337151	0.837662846	.	.	.	.	.	1840.35634	7.91225	1.0	0.010	T	0.0	0.026	B	0.0	0.013	B	.	.	.	1	0.090	P	-2.115	0.002	N	3.24	0.069	T	1.63	0.006	N	0.112	0.121	-0.995	0.313	T	0.000	0.000	T	.	.	.	-1.238	0.024	0.006	0.266	0.013	0.001	0.006	N	c	-2.131	-2.096	0.000	0.012	0.487	0.133	0	-0.806	0.103	-1.663	0.021	-1.836	0.006	0.000	0.063	0.000	0.016	4.388	0.107	.	ENSG00000229676.2|ENSG00000229676.2|ENSG00000261558.1|ENSG00000229676.2	Adipose_Subcutaneous|Cells_Transformed_fibroblasts|Testis|Testis	0.5	64	14	chr19	22942325	chr19:22942325	G	C	64	PASS	AN=2;DP=14	GT	0/1
chr19	37063218	37063218	-	A	intronic	ZNF529	.	.	.	0.001067137	0.827361965	0.171570898	.	0.14576	.	-0.26993514	34.59542345	37.91119	1.12549	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	52	17	chr19	37063218	chr19:37063218	C	CA	52	PASS	AN=2;DP=17	GT	0/1
chr19	42595481	42595483	GGA	-	UTR3	POU2F2	NM_001247994:c.*276_*274delTCC;NM_002698:c.*223_*221delTCC;NM_001207025:c.*223_*221delTCC	.	.	0.97379428	0.026199392	6.33E-06	.	0.49246	0.27788	-0.538132194	20.26421326	113.2753	2.31761	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	79	chr19	42595480	chr19:42595480	TGGA	T	57	PASS	AN=2;DP=79	GT	0/1
chr19	49606750	49606750	C	-	intronic	SNRNP70	.	.	.	0.993095086	0.006904675	2.39E-07	.	0.54826	0.24974	.	.	34.51837	1.05414	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	92	312	chr19	49606749	chr19:49606749	TC	T	92	PASS	AN=2;DP=312	GT	0/1
chr19	49978960	49978962	CTG	-	exonic	FLT3LG	.	nonframeshift deletion	FLT3LG:NM_001204503:exon2:c.46_48del:p.L20del,FLT3LG:NM_001204502:exon3:c.46_48del:p.L20del,FLT3LG:NM_001459:exon3:c.46_48del:p.L20del	0.950828698	0.049022409	0.000148893	.	0.24328	0.14299	-0.560178693	19.30879925	10.2966	0.3755	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	61	94	chr19	49978959	chr19:49978959	CCTG	C	61	PASS	AN=2;DP=94	GT	0/1
chr19	52825329	52825329	C	T	exonic	ZNF480	.	stopgain	ZNF480:NM_001297624:exon4:c.C697T:p.R233X,ZNF480:NM_001297625:exon4:c.C595T:p.R199X,ZNF480:NM_144684:exon5:c.C826T:p.R276X	2.36E-07	0.709297411	0.290702353	.	0.16427	.	-0.710864321	14.5730125	759.20608	5.46015	.	.	.	.	.	.	.	.	.	.	.	.	1	0.810	D	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	4.770	0.640	24.7	0.794	0.123	0.001	0.004	N	c	-0.931	-1.423	0.987	0.312	0.563	0.310	0	-4.51	0.032	-5.225	0.002	-1.307	0.013	0.000	0.063	0.000	0.016	2.255	0.038	Zinc finger C2H2-type/integrase DNA-binding domain|Zinc finger, C2H2|Zinc finger, C2H2-like	.	.	0.5	51	50	chr19	52825329	chr19:52825329	C	T	51	PASS	AN=2;DP=50	GT	0/1
chr20	9416190	9416190	-	T	intronic	PLCB4	.	.	.	0.272263498	0.727736501	6.10E-10	.	0.12302	0.14602	-0.907472583	10.07313046	4614.82682	13.64468	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	16	chr20	9416190	chr20:9416190	G	GT	42	PASS	AN=2;DP=16	GT	0/1
chr20	33555031	33555031	A	-	intronic	MYH7B	.	.	.	1.33E-23	0.792349353	0.207650647	.	0.15291	0.32389	-0.893455413	10.17338995	2287.01575	8.85125	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	60	19	chr20	33555030	chr20:33555030	TA	T	60	PASS	AN=2;DP=19	GT	0/1
chr20	57523229	57523229	C	T	intergenic	GNAS;NELFCD	dist=36978;dist=33034	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	67	99	chr20	57523229	chr20:57523229	C	T	67	PASS	AN=2;DP=99	GT	0/1
chr21	18924237	18924237	T	G	exonic	CXADR	.	synonymous SNV	CXADR:NM_001207063:exon3:c.T381G:p.G127G,CXADR:NM_001207064:exon3:c.T381G:p.G127G,CXADR:NM_001207066:exon3:c.T381G:p.G127G,CXADR:NM_001338:exon3:c.T381G:p.G127G	0.342891275	0.654169916	0.00293881	.	.	0.2281	-0.005381972	53.50908233	105.35884	2.22286	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	58	67	chr21	18924237	chr21:18924237	T	G	58	PASS	AN=2;DP=67	GT	0/1
chr21	33078562	33078562	T	A	intronic	SCAF4	.	.	.	0.999999693	3.07E-07	5.92E-18	.	0.7639	0.10408	-1.214341017	5.67940552	104.06406	2.20474	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	50	39	chr21	33078562	chr21:33078562	T	A	50	PASS	AN=2;DP=39	GT	0/1
chr21	33078569	33078569	G	A	intronic	SCAF4	.	.	.	0.999999693	3.07E-07	5.92E-18	.	0.7639	0.10408	-1.214341017	5.67940552	104.06406	2.20474	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	27	chr21	33078569	chr21:33078569	G	A	.	PASS	AN=0;DP=27	GT	0/1
chr21	38092248	38092248	A	-	intronic	SIM2	.	.	.	0.178825369	0.820642349	0.000532282	.	0.36242	0.24747	-0.198338176	39.17197452	2208.64464	8.65301	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	74	57	chr21	38092247	chr21:38092247	GA	G	74	PASS	AN=2;DP=57	GT	0/1
chr22	20137322	20137322	A	G	UTR5	CCDC188	NM_001243537:c.-61T>C	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	84	83	chr22	20137322	chr22:20137322	A	G	84	PASS	AN=2;DP=83	GT	0/1
chr22	21470406	21470406	C	T	ncRNA_intronic	BCRP2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	.	143	chr22	21470406	chr22:21470406	C	T	.	PASS	AN=0;DP=143	GT	0/1
chr22	21583596	21583597	CT	-	intronic	GGT2	.	.	.	0.80481651	0.190051731	0.005131759	.	.	0.11718	.	.	1425.85016	7.053	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	69	34	chr22	21583595	chr22:21583595	ACT	A	69	PASS	AN=2;DP=34	GT	0/1
chr22	39418780	39418780	-	C	intronic	APOBEC3D	.	.	.	2.36E-05	0.912736699	0.087239749	.	.	0.04922	-0.157884861	42.05590941	49.3236	1.37327	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	119	73	chr22	39418780	chr22:39418780	T	TC	119	PASS	AN=2;DP=73	GT	0/1
chr22	39496336	39496336	G	T	exonic	APOBEC3H	.	nonsynonymous SNV	APOBEC3H:NM_001166002:exon2:c.G53T:p.R18L,APOBEC3H:NM_001166003:exon2:c.G53T:p.R18L,APOBEC3H:NM_001166004:exon2:c.G53T:p.R18L,APOBEC3H:NM_181773:exon2:c.G53T:p.R18L	0.637623187	0.355699123	0.00667769	.	0.03807	0.11857	0.705562627	85.52724699	3553.79975	11.52391	0.142	0.270	T	0.989	0.609	D	0.925	0.643	D	.	.	.	1	0.090	P	1.845	0.488	L	0.04	0.634	T	-2.22	0.501	N	0.173	0.210	-1.017	0.247	T	0.000	0.000	T	.	.	.	2.007	0.302	16.25	0.986	0.437	0.019	0.058	N	c	-0.661	-0.923	1.000	0.517	0.560	0.301	0	-0.212	0.125	-0.116	0.106	-0.317	0.077	0.000	0.063	0.000	0.016	5.159	0.143	Cytidine and deoxycytidylate deaminases, zinc-binding	ENSG00000226024.1|ENSG00000243811.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000226024.1|ENSG00000239713.3|ENSG00000239713.3|ENSG00000243811.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000128394.12|ENSG00000239713.3|ENSG00000226024.1|ENSG00000243811.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000226024.1|ENSG00000239713.3|ENSG00000226024.1|ENSG00000226024.1|ENSG00000243811.3|ENSG00000239713.3|ENSG00000239713.3|ENSG00000226024.1|ENSG00000239713.3|ENSG00000239713.3|ENSG00000239713.3	Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Subcutaneous|Adipose_Visceral_Omentum|Artery_Aorta|Artery_Tibial|Artery_Tibial|Breast_Mammary_Tissue|Cells_Transformed_fibroblasts|Cells_Transformed_fibroblasts|Colon_Sigmoid|Esophagus_Mucosa|Esophagus_Mucosa|Esophagus_Muscularis|Esophagus_Muscularis|Esophagus_Muscularis|Heart_Atrial_Appendage|Heart_Left_Ventricle|Lung|Lung|Muscle_Skeletal|Nerve_Tibial|Nerve_Tibial|Nerve_Tibial|Skin_Not_Sun_Exposed_Suprapubic|Skin_Sun_Exposed_Lower_leg|Skin_Sun_Exposed_Lower_leg|Thyroid|Vagina	0.5	95	36	chr22	39496336	chr22:39496336	G	T	95	PASS	AN=2;DP=36	GT	0/1
chr22	46709700	46709700	A	G	intronic	GTSE1	.	.	.	6.90E-06	0.900506171	0.099486926	.	0.10167	0.0686	0.854236942	88.51144138	773.1469	5.50331	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	45	65	chr22	46709700	chr22:46709700	A	G	45	PASS	AN=2;DP=65	GT	0/1
chr22	50488632	50488632	C	T	exonic	TTLL8	.	synonymous SNV	TTLL8:NM_001350317:exon4:c.G204A:p.R68R	.	.	.	.	0.72788	0.09578	.	.	3618.46748	11.65843	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	89	chr22	50488632	chr22:50488632	C	T	53	PASS	AN=2;DP=89	GT	0/1
chrX	38240578	38240578	T	-	intronic	OTC	.	.	.	0.9810179	0.01896801	1.41E-05	DISEASE: Ornithine carbamoyltransferase deficiency (OTCD) [MIM:311250]: An X-linked disorder of the urea cycle which causes a form of hyperammonemia. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. The disorder is treatable with supplemental dietary arginine and low protein diet. The arbitrary classification of patients into the 'neonatal' group (clinical hyperammonemia in the first few days of life) and 'late' onset (clinical presentation after the neonatal period) has been used to differentiate severe from mild forms. {ECO:0000269|PubMed:10070627, ECO:0000269|PubMed:10502831, ECO:0000269|PubMed:10737985, ECO:0000269|PubMed:11793483, ECO:0000269|PubMed:1480464, ECO:0000269|PubMed:1671317, ECO:0000269|PubMed:1721894, ECO:0000269|PubMed:2347583, ECO:0000269|PubMed:2474822, ECO:0000269|PubMed:3170748, ECO:0000269|PubMed:7474905, ECO:0000269|PubMed:7951259, ECO:0000269|PubMed:8019569, ECO:0000269|PubMed:8081373, ECO:0000269|PubMed:8081398, ECO:0000269|PubMed:8099056, ECO:0000269|PubMed:8530002, ECO:0000269|PubMed:8807340, ECO:0000269|PubMed:8830175, ECO:0000269|PubMed:8956038, ECO:0000269|PubMed:8956045, ECO:0000269|PubMed:9143919, ECO:0000269|PubMed:9266388, ECO:0000269|PubMed:9286441, ECO:0000269|PubMed:9452024, ECO:0000269|PubMed:9452049, ECO:0000269|PubMed:9452065, ECO:0000269|Ref.32, ECO:0000269|Ref.43}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.22278	0.85665	0.082802743	60.09082331	1072.1412	6.27812	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	57	25	chrX	38240577	chrX:38240577	CT	C	57	PASS	AN=2;DP=25	GT	0/1
chrX	41094954	41094954	-	T	UTR3	USP9X	NM_001039591:c.*3177_*3178insT;NM_001039590:c.*3177_*3178insT	.	.	1	2.36E-11	2.78E-27	.	0.58131	0.10304	-1.618506764	2.925218212	35.92323	1.07855	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	42	17	chrX	41094954	chrX:41094954	G	GT	42	PASS	AN=2;DP=17	GT	0/1
chrX	47034512	47034512	C	-	intronic	RBM10	.	.	.	0.999912181	8.78E-05	2.82E-11	DISEASE: TARP syndrome (TARPS) [MIM:311900]: A disorder characterized by the Robin sequence (micrognathia, glossoptosis and cleft palate), talipes equinovarus and cardiac defects. {ECO:0000269|PubMed:20451169}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.17567	0.15702	-0.66859065	15.76433121	77.16708	1.84454	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	49	50	chrX	47034511	chrX:47034511	AC	A	49	PASS	AN=2;DP=50	GT	0/1
chrX	119658624	119658624	-	T	UTR3	CUL4B	NM_003588:c.*1991_*1992insA;NM_001330624:c.*1991_*1992insA;NM_001079872:c.*1991_*1992insA	.	.	0.999846678	0.000153322	1.10E-10	DISEASE: Mental retardation, X-linked, syndromic, 15 (MRXS15) [MIM:300354]: A syndromic form of X-linked mental retardation characterized by severe intellectual deficit associated with short stature, craniofacial dysmorphism, small testes, muscle wasting in lower legs, kyphosis, joint hyperextensibility, pes cavus, small feet, and abnormalities of the toes. Additional neurologic manifestations include speech delay and impairment, tremor, seizures, gait ataxia, hyperactivity and decreased attention span. {ECO:0000269|PubMed:17236139, ECO:0000269|PubMed:17273978, ECO:0000269|PubMed:19377476, ECO:0000269|PubMed:20002452}. Note=The disease is caused by mutations affecting the gene represented in this entry.; 	0.87445	0.12121	-0.361761279	28.6329323	9.19638	0.33598	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	0.5	53	35	chrX	119658624	chrX:119658624	C	CT	53	PASS	AN=2;DP=35	GT	0/1
